


 Cite this: *RSC Adv.*, 2022, 12, 24887

Chemical diversity, medicinal potentialities, biosynthesis, and pharmacokinetics of anthraquinones and their congeners derived from marine fungi: a comprehensive update†

 Mohamed Sebak,¹ Fatma Molham,² Claudio Greco,³ Mohamed A. Tammam,⁴ Mansour Sobeh⁵ and Amr El-Demerdash^{1*}

Marine fungi receive excessive attention as prolific producers of structurally unique secondary metabolites, offering promising potential as substitutes or conjugates for current therapeutics, whereas existing research has only scratched the surface in terms of secondary metabolite diversity and potential industrial applications as only a small share of bioactive natural products have been identified from marine-derived fungi thus far. Anthraquinones derived from filamentous fungi are a distinct large group of polyketides containing compounds which feature a common 9,10-dioxoanthracene core, while their derivatives are

 Received 11th June 2022
 Accepted 14th August 2022

DOI: 10.1039/d2ra03610j

rsc.li/rsc-advances
¹Microbiology and Immunology Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt

²Molecular Microbiology Department, The John Innes Center, Norwich Research Park, Norwich NR4 7UH, UK

³Department of Biochemistry, Faculty of Agriculture, Fayoum University, Fayoum 63514, Egypt

⁴AgroBioSciences Department, Mohammed VI Polytechnic University (UM6P), Ben Guerir, Morocco

⁵Organic Chemistry Division, Department of Chemistry, Faculty of Science, Mansoura University, Mansoura 35516, Egypt. E-mail: a_eldemerdash83@mans.edu.eg; Amr.El-Demerdash@jic.ac.uk; Tel: +00447834240424

[†]Department of Metabolic Biology and Biological Chemistry, The John Innes Center, Norwich Research Park, Norwich NR4 7UH, UK

 † Electronic supplementary information (ESI) available. See <https://doi.org/10.1039/d2ra03610j>


Dr. Mohamed Sebak was awarded a bachelor's degree in Pharmaceutical Sciences (Excellent with honor degree) from the Faculty of Pharmacy, Beni-Suef University (Egypt) and he received his M.Sc. degree (December 2013) in Microbiology and Immunology from the Faculty of Pharmacy, Beni-Suef University. Then, he obtained his Joint Supervision PhD degree (March 2020) in Microbial

Natural Products Metabolomics according to a channel system between Beni-Suef University and the University of Strathclyde, Glasgow (UK) after two years of a research study in the UK (2016–2018) under supervision of Dr RuAngelie Edrada-Ebel, before starting his new job as a Lecturer of Microbiology and Immunology at Beni-Suef University, while he started his postdoctoral studies in the same University afterwards. Mohamed's main research interests include microbial natural product discovery, LC-MS- and NMR-based metabolomics, antimicrobial resistance, antimicrobial peptides, and biofilm.



Dr. Fatma Molham was awarded a bachelor's degree in Pharmaceutical Sciences (excellent with honors) from the Faculty of Pharmacy, Beni-Suef University (Egypt) and she received her M.Sc. degree (October 2016) in Microbiology and Immunology from the same university. She obtained her PhD degree (April 2021) in Microbiology and Immunology from the Faculty of Pharmacy, Beni-Suef

University. Then, she started her new job as a Lecturer of Microbiology and Immunology at Beni-Suef University. Fatma's main research interests include bacteriocins, antimicrobial peptides, antimicrobial resistance, biofilm, and microbial natural products.



generated through enzymatic reactions such as methylation, oxidation, or dimerization to produce a large variety of anthraquinone derivatives. A considerable number of reported anthraquinones and their derivatives have shown significant biological activities as well as highly economical, commercial, and




Dr. Claudio Greco received a PhD at the University of Bristol (2017) elucidating the biosynthesis of fungal secondary metabolites under the supervision of Prof. Russell Cox and Prof. Chris Willis. This was followed by a two-year Postdoc at the University of Wisconsin–Madison working with Prof. Nancy Keller, studying secondary metabolism regulation in pathogenic fungi. Claudio

is currently working at the John Innes Centre with Prof. Barrie Wilkinson as a BBSRC Discovery Fellow investigating the ecological role of fungal natural products and he will start a Lecturer position at Swansea University in October 2022.



Dr. Sobeh holds a BSc in Chemistry from Ain Shams University, Egypt, an MSc in Analytical Chemistry from the German University in Cairo, Egypt, and a PhD in Natural Sciences (Dr rer. nat.) from Heidelberg University – Germany. Dr Sobeh is currently an Assistant Professor at Mohammed VI Polytechnic University, Morocco. His ongoing research focuses on valorizing the biomass of African

plants and agro- and industrial wastes for the provision of novel chemical entities that can be used as plant-based biostimulants, biopesticides, and bioinsecticides to secure sustainable crop production and enhance agricultural development. Sobeh is also interested in the discovery and characterization of new compounds that could pave new avenues for applications in cosmetics, nutrition, and pharmaceutical.



Dr. Mohamed Tamam obtained his BSc degree in soil and water science in 2008 (Excellent with honor), from Fayoum University, Egypt where he acquired his MSc degree in biochemistry and chemistry of natural products in 2013, and later he received his PhD degree in Pharmacy (Excellent), from the National and Kapodistrian University of Athens (NKUA) focused on isolation and structure

elucidation of secondary metabolites from marine organisms of the Red Sea under the joint mentorship of Prof. Vassilios Roussis and Prof. Efstathia Ioannou in 2020. After completing his PhD in Greece, he was promoted to lecturer in the Biochemistry Department, Faculty of Agriculture Fayoum University, Egypt. Subsequently, since May 2021 till now he is doing his postdoctoral research focusing on isolation and structure elucidation of secondary metabolites from marine organisms, in the Section of Pharmacognosy and Chemistry of Natural Products, Department of Pharmacy, School of Health Sciences, (NKUA) with Prof. Vassilios Roussis and Prof. Efstathia Ioannou. His research interests are on bioactive natural products from marine macro- and microorganisms.



Dr. Amr El-Demerdash received his BSc degree (excellent with honors, 85.6%, ranked 4th) in chemistry at the Faculty of Sciences, Mansoura University (Egypt) in 2004, and his MSc degree in organic chemistry (natural product chemistry) at the same university in 2009, before gaining his PhD in organic chemistry (discovery of pharmacologically active marine natural products and

biomimetic total synthesis) from the prestigious French chemical institution CNRS-ICSN (Natural Products Chemistry Institute), University of Paris-Saclay (France), under the supervision of Dr Ali Al-Mourabit, in May 2016. After pursuing his PhD in France, Dr El-Demerdash was affiliated to Mansoura University (Egypt) as assistant professor while also conducting his first postdoctoral training (October 2017 to March 2019) within the fungal natural products' chemistry group, CNRS/MNHN, Sorbonne Universities (France). Since April 2019 till now, Dr El-Demerdash is conducting his second postdoctoral training, working on the biosynthesis of pharmacologically active plant natural products (Professor Anne Osbourn's group) at the John Innes Centre, Norwich Research Park, (United Kingdom). Later, in December 2021, Dr El-Demerdash was promoted to associate professorship in organic and natural products' chemistry, at Mansoura University, Egypt. His work covers natural products chemistry including isolation, structure elucidation, biomimetic synthesis, and biosynthesis.



biomedical potentialities such as anticancer, antimicrobial, antioxidant, and anti-inflammatory activities. Accordingly, and in this context, this review comprehensively covers the state-of-art over 20 years of about 208 structurally diverse anthraquinones and their derivatives isolated from different species of marine-derived fungal genera along with their reported bioactivity wherever applicable. Also, in this manuscript, we will present in brief recent insights centred on their experimentally proved biosynthetic routes. Moreover, all reported compounds were extensively investigated for their *in-silico* drug-likeness and pharmacokinetics properties which intriguingly highlighted a list of 20 anthraquinone-containing compounds that could be considered as potential drug lead scaffolds.

1 Introduction

Throughout history, different natural sources have been used for treatment of diseases, and more recently as sources and valuable suppliers of biologically active compounds with diverse bioactivities that can be developed to be used in new drugs.^{1–6} Intriguingly, marine organisms and microorganisms were among the valuable sources of new natural products.² Microbial secondary metabolites have been known for their chemical diversity and a broad range of bioactivities.^{6,7} Marine microorganisms are considered highly productive sources of physiologically active compounds including peptides, polyketides, terpenes, and alkaloids.^{8–10} Some marine-based compounds have been approved as drugs with different pharmacological uses,^{11,12} while several others are under different clinical trials before their approval as new drugs.¹¹

During the last few decades, numerous drug discovery programs focused on marine-derived microbial natural products due to their great potential for the production of structurally diverse biologically active secondary metabolites.^{13,14} Among the hot microbes responsible for the production of interesting compounds, fungi, served as the primary source for mining the first reported antibiotic, penicillin, whereas they are still one of the main sources for discovering novel bioactive compounds from different niches including the marine fungi which have high biological diversifications.^{15,16} Therefore, the bioactive secondary metabolites recovered from the marine-derived fungi have gained great interest as promising sources of therapeutics. Interestingly, more than a thousand compounds have been isolated from marine fungi with a wide range of bioactivities including antiviral, anticancer, and antibacterial activities.¹⁷ Even though only one bioactive compound, cyclosporine A, has been approved for clinical use in the market. This might be attributed to problems in the optimization methods or the screening approaches of natural product discovery.¹⁸

Studying the marine-derived fungi has been started around two centuries ago when the first fungal species, *Sphaeria posidoniae* (*Halothia posidoniae*) was reported on a rhizome of the marine grass *Posidonia oceanica* in 1846.¹⁹ Marine fungi have been isolated from different habitats including algae, mobile, and sessile invertebrates, sediments, marine mammals, and driftwood from different marine locations.²⁰ Despite the importance of marine fungi as a promising source for novel bioactive secondary metabolites, marine fungi are still less investigated sources for natural product discovery programmes compared to other niches of fungi.^{18,21} Although the estimated

number of fungal species on the earth is ranging from 1.5 to 5 million species, only around 1100 species have been exclusively isolated from the marine niche.^{18,20}

Marine-derived fungi produce various classes of different compounds with both chemical and biological diversities.^{22,23} For instance, they produce varieties of bioactive compounds such as terpenes, alkaloids, peptides, and polyketides.¹⁸ Polyketides have been reported in many previous studies as dominant natural products from marine filamentous fungi.^{24,25} They are a large group of complex chemical architectures such as anthraquinones, hydroxyanthraquinones, naphthoquinones, macrolides, flavonoids, polyenes, and tetracyclines. Around 700 anthraquinones and their derivatives have been reported from different natural sources, while anthraquinones are widely produced by marine filamentous fungi.^{16,26} Chemically, anthraquinones are a group of polyketides of the quinone family with a basic cyclic scaffold of three fused benzene rings including two ketone groups on the central 9, 10-carbons with a chemical formula of C₁₄H₈O₂, while their derivatives are generated by the decoration of the around free protons with different functional groups¹⁶ or by enzymatic reaction of the rings or the keto groups such as reduction, oxidation, dehydration or dimerization to result in a wide range of derivatives.²⁷ Interestingly, many reported anthraquinones and their derivatives exhibited potent biological activities including antitumor, antibacterial, antifungal, antioxidant, and immunomodulatory bioactivities.¹⁶

Drug-likeness and pharmacokinetics properties using SWISSADME online platform, which intriguingly highlighted a list of 20 anthraquinone containing compounds (ESI†) that could be considered as potential drug leads scaffolds. Such a massive connection between chemical spaces and bioactivities highlights the huge capacity of marine-derived fungi as an attractive biological source that is worth further exploitations with distinguished anticipations for the global pharmaceuticals industries.

Several interesting review articles have focused recently on the marine anthraquinones and their derivatives such as Fouillaud *et al.* who reported the chemical diversity, specific bioactivities, biosynthetic pathways, biological sources, and the producing fungal genera of tens of marine-derived anthraquinones and their derivatives discovered before 2016.¹⁶ Also, another review by Masi and Evidente presented a comprehensive update of the bioactive fungal anthraquinones and analogues including the marine-derived anthraquinones produced *via* the acetate route over the period 1966–2020 with their sources, biosynthesis, biological activities, and industrial applications.²⁸ Whereas Greco



et al. in their recent review critically described the marine-derived anthraquinones which showed anti-tumor activity as well as their mutagenic and genotoxic potentialities.²⁹ Herein and as a part of our continuous program on pharmacologically active fungal natural products,^{4,30,31} we are presenting an extensive coverage over the period 2000–2020 for 208 anthraquinones and their derivatives, extensively reported from different marine-derived fungal genera such as *Nigrospora*, *Aspergillus*, *Penicillium*, *Stemphylium*, *Alternaria*, *Eurotium*, *Trichoderma*, *Halorosellinia*, and *Fusarium*. In addition, we reported here their different biological activities, drug-likeness and pharmacokinetics properties wherever applicable, in addition to a general overview of their proposed biogenesis pathway. The investigation of *in-silico* drug-likeness and pharmacokinetics properties of the marine-derived anthraquinones and their derivatives in this review could be advantageous in predicting the possibility of anthraquinones as drug candidates.

2 General biosynthetic pathway of anthraquinones

There have been extensive studies since the 1950s to determine the biosynthetic pathway of anthraquinones and the related

natural products called xanthones.^{32,33} Feeding experiments using labelled acetates in fungi, first reported by Birch *et al.*, showed that anthraquinone and xanthones are biosynthesized by polyketides.^{32,33} Genome sequencing and genetic transformation experiments have confirmed that the core structure of anthraquinones is synthesized in fungi by non-reducing polyketide synthase (nrPKS).^{34,35} This class of PKS share a common domain architecture which consists of an SAT (starter unit-ACP transacylase), KS (ketosynthase), AT (acyl transferase), PT (product template), and ACP (acyl carrier protein) (Fig. 1A). The biosynthesis of anthraquinones can be generalized using emodin (**14**) and endocrocin as examples (Fig. 1B).^{27,36} The nrPKS (MdpG) synthesize the polyketide, which is then cyclized with the loss of two water molecules by the PT domain. The polyketide is released by a metallo-hydrolase protein (MdpF) to obtain atrochrysonic carboxylic acid, which can in most cases, undergo decarboxylation by a decarboxylase (MdpH1). This is followed by spontaneous dehydration and oxidation by an anthroneoxidase (MdpH2) to afford emodin (**14**).^{27,36} Some reports also have described that the final oxidation step could occur spontaneously.³⁶ Further modification by tailoring proteins give rise to a huge diversity, these include methylation, dehydration, and dimerization.²⁷

A) Non-reducing PKS architecture



B) Emodin biosynthesis




Fig. 1 General biosynthetic pathway of anthraquinones in fungi. (A) domain architecture of the non-reducing polyketide synthase. (B) Biosynthetic pathways of the anthraquinones emodin (**14**) and endocrocin. The isotope labelling pattern is shown black bold lines and the polyketide starter unit is indicated in red.



3 Chemistry and medicinal potentialities of anthraquinones and their congeners derived from marine-derived fungi

In this manuscript, we provide extensive insights about chemical and biological investigations centered on anthraquinones and their derivatives exclusively derived from marine fungi. For the handling of this documentation, all isolated anthraquinones are classified and tabulated according to the marine fungal genera where they have been recovered along with their recorded biological potentialities whenever applicable.

3.1. Anthraquinones isolated from *Nigrospora* sp.

Ten anthraquinones or their derivatives **1–10** were reported from the marine-derived fungus *Nigrospora* sp. Nigrodiquinone A (**1**) was isolated for the first time as a new hydroanthraquinone dimer from the zoanthid-derived fungus *Nigrospora* sp.³⁷ Another four anthraquinone derivatives namely 4a-*epi*-9 α -methoxydihydrodeoxybostrycin (**2**), 10-deoxybostrycin (**3**), 3,5,8-trihydroxy-7-methoxy-2-methyl-anthracene-9,10-dione (**4**), and austrocortirubin (**5**) were reported from both sea anemone-derived³⁸ and zoanthid-derived fungus *Nigrospora* sp.,³⁷ while austrocortirubin (**5**) was also recorded from the sea fan-derived fungus *Fusarium* sp.,³⁹ and the mangrove endophytic fungi *Guignardia* sp.⁴⁰ and *Halorosellinia* sp.^{40,41} Although nigrodiquinone A (**1**) showed no antiviral or antibacterial activities,³⁷ compounds **4** and **5** displayed mild antiviral activity with IC₅₀ value of 93.7 μ M against coxsackievirus and 74.0 μ M against the respiratory syncytial virus (RSV), respectively.

Notably, compounds **2** and **3** showed potent antibacterial activity against both the Gram-positive bacteria, *Staphylococcus*

aureus and *Micrococcus tetragenus* and the Gram-negative bacteria, *Escherichia coli* (*E. coli*), *Vibrio anguillarum* (*V. anguillarum*), and *V. parahaemolyticus*. Compound **3** displayed MIC of equal to or less than 2.5 μ M against all tested bacteria, whereas compound **2** exhibited MIC of equal to or less than 2.5 μ M against all tested bacteria except *V. anguillarum* and *V. parahaemolyticus* against which it showed MIC value of 25.0 μ M.³⁸ In addition, compound **3** showed potent cytotoxic activity against the human lung cancer cell line, A-549 with an IC₅₀ value of 4.56 μ M,³⁸ while austrocortirubin (**5**) displayed an IC₅₀ value of 6.3 μ M against the human breast adenocarcinoma cells, MCF-7.³⁹

Further anthraquinone derivatives **6–10** were previously isolated from the sea anemone-derived fungus *Nigrospora* sp.³⁸ Also, some of these anthraquinone derivatives have been isolated from other marine fungal species such as *Fusarium* sp. PSU-F14 from which compounds **6–8** and **10** were recovered,³⁹ while compounds **7**, **8** and **10** were also isolated from the marine-derived fungus *Aspergillus* sp.⁴²

Compounds **6–10** exhibited different interesting biological activities. For instance, nigrosporin B (**6**) displayed modest anti-mycobacterial activity,⁴³ phytotoxic activity,⁴⁴ and potent antibacterial and cytotoxic activity.³⁸ Also, 4-deoxybostrycin (**9**) showed modest anti-mycobacterial activity,⁴³ potent antibacterial activity,³⁸ and moderate antitumor activity.⁴⁵ Nigrosporin B (**6**) and 4-deoxybostrycin (**9**) displayed potent antibacterial activity against both the Gram-positive bacteria, *Bacillus subtilis* (*B. subtilis*), *B. cereus*, *Staphylococcus albus* (*S. albus*), *S. aureus*, and *Micrococcus tetragenus* and the Gram-negative bacteria *E. coli*, *V. anguillarum*, and *V. parahaemolyticus* with MIC values equal to or less than 2.5 and 3.12 μ M, respectively.³⁸ Moreover, both compounds exhibited modest anti-mycobacterial activity against several mycobacterial species including two multidrug-resistant *Mycobacterium tuberculosis* (*M. tuberculosis*) with MIC values of less than 30.0 μ g mL⁻¹.⁴³




Fig. 2 Chemical structures of compounds **1–10**.

An additional example of anthraquinones isolated from *Nigrospora* sp. with multiple bioactivities is tetrahydrobostrycin (8) which exhibited moderate to high antibacterial activity against the Gram-positive bacteria, *B. subtilis* and *B. cereus* (MIC values of 2.5 μM), *S. aureus* and *Micrococcus luteus* (MIC values of 2.5 μM), and *Micrococcus tetragenus* (MIC value of 1.25 μM).³⁸ Compound 8 also displayed good antibacterial activity against

the Gram-negative bacteria *E. coli* (MIC value of 6.25 μM), *V. anguillarum* (MIC value of 1.56 μM), and *V. parahemolyticus* (MIC value of 12.5 μM).³⁸ Additionally, it exhibited potent activity against *M. tuberculosis* with a MIC value of 12.50 $\mu\text{g mL}^{-1}$ and was also active as antimalarial agent against *Plasmodium falciparum* with an IC_{50} value of 7.94 $\mu\text{g mL}^{-1}$ ⁴⁶ (Fig. 2).




Fig. 3 Chemical structures of compounds 11–44.



3.2. Anthraquinones isolated from *Aspergillus* sp.

Aspergillus was the richest source of marine anthraquinones and their derivatives among all marine-derived fungi with 73 reported compounds including the previously mentioned 7, 8, and 10 as well as other seventy anthraquinones 11–80. For instance, thirteen compounds 11–23 were isolated from the marine-derived fungus *Aspergillus glaucus* (*A. glaucus*).⁴⁷ Aspergiolide A (11), which features a naphtho[1,2,3-de]chromene-2,7-dione skeleton was isolated as a novel anthraquinone derivative from the marine-derived fungus *A. glaucus*.⁴⁸ Aspergiolide B (12) was isolated from

A. glaucus as a new analogue for aspergiolide A (11).⁴⁷ Aspergiolides A and B (11 and 12) exhibited potent cytotoxic activities against both adenocarcinoma human alveolar basal epithelial cell line, A-549 with IC₅₀ values of 0.13 and 0.24 μM and human leukemia cell line, HL-60 with IC₅₀ values of 0.28 and 0.51 μM, respectively^{47,48} indicating that methylation of one hydroxyl group in aspergiolide A (11) to be a methoxy group in aspergiolide B (12) slightly affected the cytotoxicity of aspergiolide A.

Physcion (13) was also isolated from other species of *Aspergillus* such as *A. glaucus*,⁴⁷ *A. wentii*,⁴⁹ and the halotolerant *A.*




Fig. 4 Chemical structures of compounds 45–80.



*varicolor*⁵⁰ besides the marine-derived fungus *Microsporium* sp.⁵¹ Phycion (13) displayed a wide array of biological activities including cytotoxic activity against human cervical carcinoma HeLa cells,⁵¹ moderate antifungal activity against *Trichophyton mentagrophytes* with a MIC value of 25.0 $\mu\text{g mL}^{-1}$ and weak antifungal activity against both *C. albicans* and *Cryptococcus neoformans* with MIC value of 50.0 $\mu\text{g mL}^{-1}$.⁵² It also exhibited weak free radical scavenging activity against 1,1-diphenyl-2-picrylhydrazyl (DPPH) with an IC₅₀ value of 99.4 $\mu\text{g mL}^{-1}$.⁴⁹

Furthermore, emodin (14) which was reported from the marine-derived fungus *A. glaucus*, was also recovered from many other marine fungal species such as *Penicillium citrinum* (*P. citrinum*),⁵³ *Trichoderma aureoviride* (*T. aureoviride*),⁵⁴ *Monodictys* sp.,⁵⁵ *Gliocladium* sp.,⁵⁶ *Paecilomyces* sp.,⁵⁷ *Eurotium rubrum* (*Eu. rubrum*)⁵⁸ and *A. versicolor*.⁵⁹ Emodin (14) showed moderate antibacterial against *Pseudomonas putida* with a MIC value of 25.0 μM ⁶⁰ and significant anti-mycobacterial activity against *M. tuberculosis* with a MIC value of 12.5 $\mu\text{g mL}^{-1}$ and modest antifungal activity against *Candida albicans* (*C. albicans*) with an IC₅₀ value of 11.0 $\mu\text{g mL}^{-1}$.⁶¹ Noteworthy, it showed potent cytotoxic activity against both oral human epidermoid carcinoma cell line, KB and human breast cancer cell line, MCF7 with IC₅₀ values of 0.88 and 2.8 $\mu\text{g mL}^{-1}$, respectively.⁶¹

Further anthraquinones 17 and 18, and 20 which were isolated from both *A. glaucus*⁴⁷ and the halotolerant *A. varicolor*,⁵⁰ showed variable bioactivities. Questin (17) and catenarin (18) exhibited DPPH radical scavenging activity⁶² and potent antibacterial activity against *Brevibacillus brevis* with a MIC value of 1.0 $\mu\text{g mL}^{-1}$,⁶³ respectively, while (+)-varicolorquinone A (20) displayed positive cytotoxicity against the human hepatocellular carcinoma cell line, BEL-7402, mouse lymphoma cell line, P388, human leukemia cell line, HL-60, and adenocarcinoma human alveolar basal epithelial cells, A-549 with IC₅₀ values of 114.0, 266.0, 309.0, and 3.0 μM , respectively.⁵⁰

Notably, the known anthraquinone dimer 21, as well as two new isomers of anthraquinone dimer 22 and 23, were also isolated from *A. glaucus*.⁴⁷ However, compound 21 was not evaluated for any relevant bioactivity, the *trans* isomer of emodin-phycion bianthrone (22) showed good cytotoxicity against the cell lines; A-549 and HL-60 with IC₅₀ values of 9.2 and 7.8 μM , respectively. On the other hand, its *cis* isomer 23 was less active as its IC₅₀ values were 14.2 and 44.0 μM , respectively,⁴⁷ suggesting that isomerization has affected the cytotoxicity of compound 22.

Additional thirty anthraquinones 24–54 have been isolated from the marine-derived fungus *A. versicolor*. Two new anthraquinone dimers 24 and 25 besides three other known closely related anthraquinone derivatives 26–28 were isolated from the marine-derived fungus *A. versicolor*.⁶⁴ Averantin (26) and its derivative 1'-*O*-methyl-averantin (27) were also isolated earlier from the marine-derived fungus *P. purpurogenum* G59 ref. 65 and *Aspergillus* sp. SCSIO F063,⁶⁶ while averyrin (28) was formerly reported from the marine-derived fungus *Aspergillus* sp. SCSIO F063.⁶⁶

Compounds 24 and 25 showed selective antibacterial activity against the Gram-positive bacterium, *S. aureus* using the disk diffusion method at a concentration of 30.0 μg per well,⁶⁴

whereas the same study revealed that compound 24 had a selective cytotoxic activity against human CNS cancer cells, XF-498 with an IC₅₀ value of 22.39 $\mu\text{g mL}^{-1}$. In addition, averantin (26) and its derivative 1'-*O*-methyl-averantin (27) displayed a weak antitumor activity against the bone marrow cancer cell line, K562 at a concentration of 100.0 $\mu\text{g mL}^{-1}$.⁶⁵ Another study mentioned that compound 27 exhibited modest cytotoxic activity against the human glioblastoma SF-268, human breast adenocarcinoma MCF-7 and human large-cell lung carcinoma NCI-H460 cell lines with IC₅₀ values ranging from 33.59 to 44.22 μM , whilst compounds 26 and 28 displayed weak to moderate cytotoxic activity against MCF-7 with IC₅₀ values of 45.47 and 29.69 μM , respectively.⁶⁶ Also, compounds 26 and 27 displayed potent antioxidant activity, whereas compound 28 exhibited weak antioxidant activity in terms of antioxidant capacity compared to Trolox⁶⁷ suggesting that the presence of oxygen in the side chain of the anthraquinones may play role in their antioxidant activity.

Additionally, compound 26 displayed promising antibacterial activity against different strains of the Gram-positive bacteria, *Streptococcus pyogenes* (*Str. pyogenes*) and *S. aureus* with MIC values of equal to or less than 3.13 $\mu\text{g mL}^{-1}$, while its 1'-*O*-methylated derivative, 27 showed weaker antibacterial activity as it was only active against one strain of *Str. pyogenes* with a MIC value of 6.25 $\mu\text{g mL}^{-1}$ with no activity against the other strain of *Str. pyogenes* or any strain of *S. aureus* up to a concentration of 12.5 $\mu\text{g mL}^{-1}$,⁶⁸ indicating that *O*-methylation at position 1 greatly affected the antibacterial activity of averantin (26).

Compound 29 which is another derivative of averantin (26) was isolated from another marine-derived fungus *A. versicolor* EN-7.⁶⁹ Compound 29 showed weak antibacterial activity against only *E. coli* at a concentration of 20.0 μg per disk with no activity against *S. aureus*,⁶⁹ suggesting that the *O,O'*-dimethylation of averantin (26) decreased its antibacterial activity against the Gram-positive bacteria.

The aflatoxin, averufin (30) and its *O*-methylated derivatives 6-*O*-methyl-averufin (31) and 6,8-*O,O'*-dimethyl-averufin (32) were also isolated from different strains of the marine-derived fungus *A. versicolor*,^{68,69} whereas averufin (30) was also isolated from other species of *Aspergillus* such as *A. niger*⁷⁰ and *A. nidulans*.⁷¹ Averufin (30) exhibited different bioactivities including potent antioxidant activity in terms of Trolox equivalent antioxidant capacity,⁶⁷ weak cytotoxic activity,⁶⁸ and moderate inhibitory activity against the multiplication of *Tobacco Mosaic virus*,⁷⁰ in addition to weak antibacterial activity against the Gram-positive *Str. pyogenes* and *S. aureus* with MIC values equal to or less than 12.5 $\mu\text{g mL}^{-1}$.⁶⁸ On the other hand, neither 6-*O*-methyl-averufin (31) nor 6,8-*O,O'*-dimethyl-averufin (32) showed any antimicrobial activity⁶⁹ or anti-neuroinflammatory effect,⁷² respectively.

Moreover, further eight bioactive compounds 33–40 were also isolated from the marine-derived fungus *A. versicolor*.^{67–69,73} including versicolorin B (33), averufanin (35) nidurufin (37), and versiconol (39) as well as their derivatives 1'-hydroxyversicolorin B (34), noraverufanin (36), 6,8-*O,O'*-dimethyl-nidurufin (38) and 6,8-*O,O'*-dimethyl-versiconol (40),



respectively. Both versicolorin B (33) and its hydroxyl derivative, 1'-hydroxyversicolorin B (34) showed potent antioxidant activity as they displayed antioxidant capacity approximately equivalent to Trolox,⁶⁷ while an old study revealed that 1'-hydroxyversicolorin B (34) (UCT1072M1) had potent cytotoxicity against the human cervical cell adenocarcinoma, HeLa S3 and the human lung giant cell carcinoma, Lu-65 with IC₅₀ values of 2.1 and 2.2 μM, respectively.⁷⁴

Indeed, averufanin (35) displayed a good antioxidant activity in terms of antioxidant capacity to Trolox,⁶⁷ and weak activity against both acyl-CoA: cholesterol acyltransferase type 1 and 2 in the cell-based assay with IC₅₀ values of 28.0 and 12.0 μM, respectively,⁷⁵ whereas noraverufanin (36) exhibited a weak HIV latency-reversal activity with reactivation of 43.3% at concentration of 10.0 μM.⁷³ Nidurufin (37) which has been also isolated from the marine fungi *A. niger*⁷⁰ as well as *P. purpurogenum* G59,⁶⁵ showed weak antitumor activity against the bone marrow cancer cell line, K562 with an inhibition rate percentage of 25.5% at a concentration of 100.0 μg mL⁻¹⁶⁵ and moderate antioxidant capacity with 0.62 as Trolox equivalent as antioxidant.⁶⁷

Another previous study showed that nidurufin (37) had exhibited strong anticancer activity against the A-549 cells, the human ovarian cancer cells, SK-OV-3, the human skin cancer cells, SK-MEL-2, the human CNS cancer cells, XF-498, and the human colon cancer HCT-15 with IC₅₀ values of 1.83, 3.39, 3.16, 1.78, and 2.2 μg mL⁻¹ beside good antibacterial activity against different strains of the Gram-positive bacteria *Str. pyogenes* and *S. aureus* with MIC values of equal to or less than 3.13 μg mL⁻¹.⁶⁸

Compound 38 (6,8-*O,O'*-dimethyl-nidurufin), showed weak antibacterial activity against the Gram-positive *S. aureus* as well as the Gram-negative *E. coli* with inhibition zones of 7 and 6.5 mm, respectively using the disk diffusion method at a concentration of 20.0 μg per disk,⁶⁹ suggesting that the new derivatization by *O,O'*-dimethylation in position 6 and 8 in this compound had affected the antibacterial activity of the parent metabolite, nidurufin (37) which showed better antibacterial activity when tested against the Gram-positive bacteria as discussed above.

Versiconol (39) exhibited weak anticancer activity against the A-549 cells, the SK-OV-3 cells, the SK-MEL-2 cells, the XF-498 cells, and the HCT-15 cells with IC₅₀ values of 20.45, 15.29, 15.86, 23.73, and 19.2 μg mL⁻¹, respectively,⁶⁸ whilst its *O,O'*-dimethylated derivative, 6,8-*O,O'*-dimethyl-versiconol (40) showed selective weak antibacterial activity against *S. aureus* with inhibition zones of 6.5 mm using disk diffusion method at a concentration of 20.0 μg per disk when tested against both *S. aureus* and *E. coli*.⁶⁹

Other bioactive compounds isolated from the marine fungus *A. versicolor* were compounds 41 and 42, 47 and 48, and 50–54.^{59,69,76} 1-methyl-emodin (41) which is an *O*-methylated derivative of emodin (14) and both were isolated from *A. versicolor*,⁵⁹ exhibited better cytotoxic activity than emodin (14) itself against human epidermoid carcinoma cell line, KBv200 with an IC₅₀ value of 190.81 μM,⁴⁰ although 41 did not show any cytotoxicity against the human leukemia cell line, CCRF-CEM and some other solid tumors including the human lung H-125, human

colon HCT-116, and human liver Hep-G2 cells.⁷⁶ On the other hand, compound 41 showed less inhibitory activity against Hepatitis C virus (HCV) protease than its parent 14 with IC₅₀ values of 40.2 and 22.5 μg mL⁻¹, respectively.⁷⁶ The same study showed that the new metabolite from *A. versicolor*; isorhodoptilometrin-1-methyl-ether (42) displayed moderate antibacterial activity against *B. cereus*, *B. subtilis*, and *S. aureus* at a concentration of 50.0 μg per disk and mild selective cytotoxicity against the Hep-G2 cell line.⁷⁶

Additionally, 1-hydroxy-2-methyl-anthraquinone (47) and its novel dimethoxy derivative; 2-(dimethoxy methyl)-1-hydroxy-9,10-anthraquinone (48) were evaluated for their antibacterial activity against two strains of methicillin-resistant *S. aureus* (MRSA) (CGMCC 1.12409 and ATCC 43300) and three strains of *Vibrio* (*V. rotiferianus*, *V. vulnificus*, and *V. campbellii*). Noteworthy, the dimethoxy derivative 48 was highly active against the MRSA strains showing MIC values of 7.8 and 3.9 μg mL⁻¹, respectively, and was moderately active against the *Vibrio* strains with MIC values ranging from 15.6 to 62.5 μg mL⁻¹.⁵⁹ The same study mentioned that a molecular docking study was conducted to explain the cause behind this antimicrobial activity revealing the least binding energy of compound 48 with both AmpC β-lactamase and topoisomerase IV (Topo IV).⁵⁹ On the other hand, its parent compound 47 displayed potent larvicidal activity against the larvae of *Aedes aegypti* with an IC₅₀ value of 1.8 μg mL⁻¹.⁷⁷

Moreover, another anthraquinone derivative, damnacanthal (50) which was reported from *A. versicolor*⁵⁹ exhibited strong larvicidal activity against the larvae of *Aedes aegypti* with an IC₅₀ value of 7.4 μg mL⁻¹⁷⁷ and weak antibacterial activity against some strains of MRSA and *Vibrio* with MIC values ranging from 31.3 to 125.0 μg mL⁻¹.⁵⁹ Similarly, xanthopurpurin (51) showed weak antibacterial properties against some strains of MRSA and *Vibrio* with the same MIC range of damnacanthal (50).⁵⁹ Also, compound 51 previously showed strong antiplatelet aggregation activity *via* inhibition of collagen-induced aggregation.⁷⁸ In addition, a chemically related rubiadin (52) showed a strong inhibitory activity on the formation of advanced glycation end products with an IC₅₀ value of 179.31 μM.⁷⁹ Notably, its hydroxylated derivative; 6-hydroxyrubiadin (53) displayed potent inhibitory activity on phosphatase of regenerating liver-3 with an IC₅₀ value of 1.3 μg mL⁻¹ causing inhibition of migration of phosphatase of regenerating liver-3 expressed tumor cells with no cytotoxicity.⁸⁰

Additional four derivatives 55–58 were isolated from the marine-derived fungus *A. wentii*.^{49,81} Wentiquinone C (55) showed no free radical scavenging activity up to a concentration of 1000.0 μg mL⁻¹,⁴⁹ whereas compounds 56–58 were not tested for any relevant bioactivity.⁸¹

Further derivatives including compounds 59–64 were isolated from the halotolerant fungus *A. varicolor*,⁵⁰ while compounds 65–67 were reported from *A. nidulans*.⁷¹ Compounds 59 and 60 exhibited potent DPPH radical scavenging activity (antioxidant activity) with IC₅₀ values of 6.0 and 11.0 μM, respectively⁵⁰ suggesting that the *O*-methylation of eurotinone (59), slightly affected its antioxidant activity. Interestingly, Questinol (62) which was also isolated from the marine-derived fungi



Talaromyces stipitatus KUFA 0207⁸² and *Eu. amstelodami*,⁸³ displayed significant anti-inflammatory activity *via* different mechanisms including inhibition of both nitric oxide and prostaglandin E2 production and, inhibition of the production of some inflammatory cytokines such as interleukin-1 β (IL-1 β), IL-6, and tumor necrosis factor- α . Compound **62** also showed slight inhibitory activity against cyclooxygenase-2 (COX-2) expression at a concentration of 200.0 μM .⁸³ In addition, compound **62** exhibited potent anti-obesity activity with a 60% reduction in the stained lipids with an IC₅₀ value of 0.95 μM , while the chemically related compound, fallacinol (**63**) showed no significant anti-obesity activity.⁸² Interestingly, versicolorin C (**65**) displayed selective potent antibacterial activity against both *E. coli* and *V. parahaemolyticus* with a MIC value of 1.0 $\mu\text{g mL}^{-1}$ and, against *V. anguillarum* and *Edwardsiella ictaluri* with MIC values of 4.0 and 8.0 $\mu\text{g mL}^{-1}$, respectively, whilst the closely related congener isoversicolorin C (**66**) displayed selective potent antibacterial activity against both *V. alginolyticus* and *Edwardsiella ictaluri* with MIC values of 1.0 and 4.0 $\mu\text{g mL}^{-1}$, respectively.⁷¹ Further, twelve anthraquinones including three non-halogenated ones **68–70**, seven new chlorinated anthraquinone derivatives **71–77**, and two new brominated anthraquinone derivatives **78** and **79** were isolated from the marine-derived fungus *Aspergillus* sp. SCSIO F063,⁶⁶ in addition to compound **80** which was reported from another marine-derived fungus *Aspergillus* sp. SF-6796.⁷² Compounds **68–70** are chemically related to each other and are derivatives of averantin (**26**) which was isolated in the same study as a metabolite from *Aspergillus* sp. SCSIO F063,⁶⁶ while it was isolated earlier from the marine-derived fungi *A. versicolor*.⁶⁴ Averantin-1'-butyl-ether (**70**) exhibited weak cytotoxicity against SF-268 and MCF-7 cell lines with IC₅₀ values of 47.19 and 40.47 μM , respectively, revealing slightly better cytotoxicity than its parent; averantin (**26**) which only showed activity against the MCF-7 cell line with an IC₅₀ value of 45.47 μM ,⁶⁶ suggesting that the structural modification in **70** has improved its bioactivity. By contrast, neither compound **68** nor **69** displayed any cytotoxicity against all tested human cell lines including NCI-H460, SF-268, and MCF-7 ref. 66 indicating that O-methylation of averantin (**26**) in compounds **68** and **69** may negatively influence their cytotoxicity. It is noteworthy that the chlorinated anthraquinone derivative, **72** exhibited potent cytotoxicity against NCI-H460, SF-268, and MCF-7 cells with IC₅₀ values of 7.42, 7.11, and 6.64 μM , respectively. While **71** showed weak cytotoxicity against only the MCF-7 cell line with an IC₅₀ value of 36.41 μM , **73** displayed better cytotoxic activity against the three cell lines; NCI-H460, SF-268, and MCF-7 with IC₅₀ values of 37.19, 34.06 and 26.09 μM , respectively.⁶⁶ The other chlorinated anthraquinones, **75** and **77** demonstrated weak to modest cytotoxic activity against only the MCF-7 cell line with IC₅₀ values of 49.53 and 24.38 μM , respectively. The same study revealed that from the two isolated brominated anthraquinones, only **78** displayed modest cytotoxicity against NCI-H460, SF-268, and MCF-7 cell lines with IC₅₀ values of 18.91, 24.69, and 25.62 μM , respectively.⁶⁶ Furthermore, another bioactive derivative of averantin (**26**) isolated from *Aspergillus* sp. is 6,8,1'-O,O',O''-trimethyl-averantin (**80**) which showed an anti-neuroinflammatory effect *via* different mechanisms including suppression of the overproduction of many pro-

inflammatory mediators including COX-2, prostaglandin E2, and nitric oxide in lipopolysaccharide-activated BV2 microglial cells⁷² (Fig. 3 and 4).

3.3. Anthraquinones from *Penicillium* sp.

Furthermore, eighteen compounds **81–98** besides the previously reported compounds **14**, **17**, **26**, **27**, and **37** were isolated from different species of the marine-derived fungus *Penicillium*. Indeed, penicillanthranin A (**81**) and B (**82**) which are anthraquinone-citrinin derivatives, as well as chrysophanol (**83**) and ω -hydroxyemodin (**84**), were isolated from the marine fungus *P. citrinum* PSU-F51.⁵³ Penicillanthranin A (**81**) and chrysophanol (**83**) exhibited selective antibacterial activity against the Gram-positive *S. aureus* ATCC25923 with MIC value of 16.0 $\mu\text{g mL}^{-1}$ for both compounds and MRSA SK1 with MIC values of 16.0 and 64.0 $\mu\text{g mL}^{-1}$, respectively, while compounds **82** and **84** were not screened for their antimicrobial activity in the same study.⁵³ Interestingly, some earlier studies revealed that ω -hydroxyemodin (**84**) showed moderate activity against MRSA SK1 and mild activity against *S. aureus* ATCC 25923 with MIC values of 32.0 and 200.0 $\mu\text{g mL}^{-1}$, respectively,⁵⁴ in addition to good anti-mycobacterial activity against *M. tuberculosis* H37Ra with a MIC value of 12.5 $\mu\text{g mL}^{-1}$.⁶¹ It also showed potent cytotoxicity against the human oral epidermoid carcinoma KB cells with an IC₅₀ value of 4.5 $\mu\text{g mL}^{-1}$, and weak cytotoxic activity against both the human breast cancer cells, MCF7 and the human lung carcinoma cells, NCI-H187 with IC₅₀ values of 22.0 and 39.0 $\mu\text{g mL}^{-1}$, respectively.⁶¹ In contrast, penicillanthranin A (**81**) showed selective cytotoxicity to the KB cell lines with an IC₅₀ value of 30.0 $\mu\text{g mL}^{-1}$.⁵³

Another bioactive metabolite, 2'-acetoxy-7-chlorocitreorsein (**85**) which was first recovered from a mangrove-derived fungus *P. citrinum* HL-5126 ref. 84 demonstrated moderate antibacterial activity against *S. aureus* and significant activity against *V. parahaemolyticus* with MIC values of 22.8 and 10.0 $\mu\text{g mL}^{-1}$, respectively,⁸⁴ suggesting that such modification in its structure by acetylation, chlorination, and O-methylation of ω -hydroxyemodin (**84**) resulted in significant improvement in its antibacterial activity. Further anthraquinone derivatives discovered from the marine fungus *P. oxalicum*, including citreorsein-3-O-sulphate (**86**), emodin-3-O-sulphate (**87**), and aloe-emodin (**88**) were not tested for any relevant activity.⁸⁵ However, other previous studies revealed that aloe-emodin (**88**) displayed modest antimalarial activity against *Plasmodium falciparum* (MRC-2) with an EC₅₀ value of 22.0 $\mu\text{g mL}^{-1}$ ⁸⁶ and weak antimicrobial activity against the Gram-positive bacteria, *S. aureus*, *S. epidermidis*, *B. cereus*, *B. subtilis*, and *Micrococcus kristinae*, and the Gram-negative bacteria, *E. coli*, *Enterobacter aerogenes*, *Proteus vulgaris*, and *Shigella sonnei* with MIC values ranging from 62.5 to 250.0 $\mu\text{g mL}^{-1}$.⁸⁷

Additional ten bioactive compounds including eight newly isolated anthraquinone-amino acid conjugates, namely emodacidamide A-H (**89–96**) along with the previously isolated anthraquinone derivatives; emodic acid (**97**) and 2-chloro-1,3,8-trihydroxy-6 (hydroxymethyl)-anthracene-9,10 dione (**98**), were isolated from the marine fungus *Penicillium* sp. SCSIO sof101.⁸⁸






Fig. 5 Chemical structures of compounds 81–98.

Emodacidamides A–H (89–96) displayed immunomodulatory activity with inhibitory activity against IL-2 production from Jurkat cells.⁸⁸ Intriguingly, emodacidamides A (89), C (91), and E (93) showed potent IL-2 inhibitory activity with IC_{50} values of 4.1, 5.1, and 5.4 μM , respectively.⁸⁸ Meanwhile, emodic acid (97) showed no remarkable inhibition of IL-2 secretion at a concentration of 20.0 μM , indicating that amino acid conjugation with the anthraquinone derivatives enhanced their inhibitory effect on IL-2 secretion.⁸⁸

On the other side, emodic acid (97) which was previously isolated from the marine endophytic fungus *Eu. rubrum*,⁵⁸ evoked potent inhibition of p56^{lck} tyrosine kinase with an IC_{50} value of 1.07 $\mu\text{g mL}^{-1}$.⁸⁹ In addition, compound 97 demonstrated a potent inhibitory effect on both the tyrosine kinase domain of the epidermal growth factor receptor and protein tyrosine kinase p59^{lyn} with IC_{50} values of 0.078 and 0.080 $\mu\text{g mL}^{-1}$, respectively without any noted cytotoxicity on human foreskin fibroblast⁸⁹ (Fig. 5).

3.4. Anthraquinones from *Stemphylium* sp.

The marine-derived fungus *Stemphylium* is another good source of the bioactive anthraquinones with thirty-two recovered compounds 99–130. A group of twenty-five anthraquinone derivatives 99–123 were reported from a mangrove-derived fungus *Stemphylium* sp. 33 231 ref. 90 including the bioactive

altersolanol A, B, C (99, 101, 104) and L (105) as well as their derivatives dihydroaltersolanol A (100), tetrahydroaltersolanol B (102), 2-*O*-acetylaltersolanol B (103).

Altersolanol A (99) showed selective antimicrobial activity against *S. aureus*, *E. coli*, *B. subtilis*, and *Micrococcus tetragenus* with MIC values of 2.07, 4.1, 4.1, and 8.2 μM , respectively, whereas altersolanol B (101) displayed similar antibacterial activity against *S. aureus*, *E. coli* and *B. subtilis* as well as the Gram-positive bacterium, *Kocuria rhizophila* with MIC values of 7.8 μM for all strains.⁹⁰ The same study revealed that altersolanol C (104) had a narrow spectrum of activity against only *B. subtilis* with a MIC value of 8.8 μM , while altersolanol L (105) had no antibacterial activity against the tested strains.⁹⁰ In the contrast, another recent study demonstrated that altersolanol L (105), had a modest antifungal activity against *P. italicum* and *Rhizoctonia solani* with MIC values of 35.0 and 50.0 $\mu\text{g mL}^{-1}$, respectively.⁹¹

Additionally, a recent study showed that both altersolanol A (99) and B (101) had strong cytotoxicity against MCF-7 and HCT-116 cell lines with IC_{50} values of [7.21, 1.3 μM] for altersolanol A (99) and, [9.0, 3.5 μM] for altersolanol B (101), respectively.⁹² By contrast, dihydroaltersolanol A (100) did not show any antibacterial activity or cytotoxicity when tested against various microbes and cell lines,^{90,93} suggesting that the derivatization of its parent altersolanol A (99) into dihydroaltersolanol A (100) lead to a significant change in its biological activities.



Furthermore, ampelanol (**107**), macrosporin (**108**) and its sulphate derivative, macrosporin-7-*O*-sulphate (**109**), in addition to its glycosidic derivative, macrosporin 2-*O*-(6'-acetyl)- α -D-glucopyranoside (**110**), as well as auxarthrol C (**111**), were also recovered from the marine fungus *Stemphylium* sp. 33 231.⁹⁰ Ampelanol (**107**) displayed moderate cytotoxicity against the murine lymphoma cell line, L5178Y,⁹⁴ whereas macrosporin (**108**) exhibited significant antibacterial activity against *Micrococcus tetragenus*, *E. coli*, and *S. aureus* with MIC values of 4.6, 4.6, and 9.2 μM , respectively.⁹⁰ On the other hand, both derivatives of macrosporin (**108**), macrosporin-7-*O*-sulphate (**109**) and macrosporin 2-*O*-(6'-acetyl)- α -D-glucopyranoside (**110**) displayed no antibacterial activity against the same indicator strains up to a concentration of 10.0 μM ,⁹⁰ indicating that these modifications in the chemical structure of macrosporin (**108**) have greatly affected its antibacterial activity. Additionally, macrosporin (**108**) was shown to have potent antifungal activity against *Fusarium oxysporum* (*F. oxysporum*) with a MIC value of 3.75 $\mu\text{g mL}^{-1}$ and modest antifungal activity against *Colletotrichum musae*, *F. graminearum*, *P. italicum*, and *Colletotrichum gloeosporioides* with MIC values ranging from 30.0 to 60.0 $\mu\text{g mL}^{-1}$.⁹¹ Noteworthy, compound **110** demonstrated a remarkable brine shrimp lethality using *Artemia salina* with an LD₅₀ value of 10.0 μM ,⁹⁰ while the parent compound **108**, and its derivative **109** showed no lethality in the same study⁹⁰ suggesting that brine shrimp lethality might be dependent on acetylation and/or glycosylation of this compound. Also, the same study revealed that auxarthrol C (**111**) displayed selective antibacterial activity against only the Gram-negative organism, *E. coli* with a MIC value of 9.8 μM with no notable cytotoxicity or brine shrimp lethal effect.⁹⁰

Moreover, other bioactive anthraquinone dimers including alterporriols B-E (**113–116**), N (**117**), Q (**118**), U (**121**), and V (**122**) were also isolated from the same fungus *Stemphylium* sp. 33 231.⁹⁰ The anthraquinone dimers, alterporriols B–E (**113–116**) displayed positive antibacterial activity, whereas alterporriol A (**112**) did not show either antibacterial or cytotoxic activity.⁹⁰ Alterporriol B (**113**) showed a narrow spectrum of antimicrobial activity against *B. cereus* with a MIC value of 7.9 μM , whereas alterporriol C (**114**) showed selective antibacterial activity against *S. albus* with a MIC value of 8.9 μM . Interestingly, alterporriol D (**115**) exhibited notable antibacterial activity against both *S. aureus* and *E. coli* and with MIC values of 5.0 and 7.5 μM , respectively, while alterporriol E (**116**) displayed potent antimicrobial activity against both *B. cereus* and *E. coli* with MIC values of 2.5 and 5.0 μM , respectively.⁹⁰ The same study demonstrated that alterporriol Q (**118**) and R (**119**) showed no antimicrobial activity against various tested microbes up to a concentration of 10.0 μM .⁹⁰ This finding was confirmed in another study which showed that both compounds did not display any antibacterial activity against different Gram-positive bacteria as well as *E. coli* from the Gram-negative bacteria up to a concentration of 20.0 μM .⁹³ However, alterporriol Q (**118**) exhibited strong antiviral activity against the porcine reproductive and respiratory syndrome virus with a MIC value of 22.0 μM , whereas alterporriol R (**119**) showed no antiviral activity.⁹³ Also, the same study revealed that alterporriol C

(**114**) had a modest antiviral activity with a MIC value of 39.0 μM .⁹³ In addition, the other anthraquinone dimers, alterporriol U (**121**) and V (**122**) exhibited a narrow spectrum of antibacterial bioactivity against the Gram-positive bacterium, *B. cereus* with MIC values of 8.3 and 8.1 μM , respectively.⁹⁰

Further anthraquinone dimers including alterporriol N (**117**), F (**124**), G (**125**), Z1 (**126**), Z2 (**127**), and Z3 (**128**) were also isolated recently from another marine fungus *Stemphylium* sp. FJJ006.⁹⁵ They showed neither antimicrobial activity against the Gram-positive and Gram-negative bacterial strains up to a concentration of 128.0 $\mu\text{g mL}^{-1}$ nor antitumor activity against a panel of cancer cell lines with an IC₅₀ value higher than 20.0 μM . Also, they did not show bioactivity against the microbial enzymes, isocitrate lyase, and sortase A with an IC₅₀ value of more than 145.0 μM . However, the same study revealed that alterporriols N (**117**), F, G, and Z1–Z2 (**124–127**) had anti-inflammatory activity through their capability of suppressing the lipopolysaccharide-induced nitric oxide production in the murine macrophages RAW 264.7 cells with IC₅₀ values of 8.4, 9.6, 10.7, 11.6, and 16.1 μM , respectively, whereas alterporriol Z3 (**128**) did not display any anti-inflammatory activity.⁹⁵ On the other hand, another previous study demonstrated the potent cytotoxicity of alterporriol F (**124**) against the HeLa and KB human cell lines with IC₅₀ values of 6.5 and 7.0 $\mu\text{g mL}^{-1}$, respectively.⁹⁶ In addition, alterporriol N (**117**) was presented in another study as a weak antimicrobial agent with a narrow spectrum of activity against only the Gram-positive bacteria, *Enterococcus faecalis*, MRSA, and *Str. pneumoniae* with MIC values of 15.63, 62.5, and 125.0 $\mu\text{g mL}^{-1}$, respectively, while the same study revealed that alterporriol G (**125**) had a moderate cytotoxicity against the mouse cancer cell line, L5178Y⁹⁷ (Fig. 6 and 7).

3.5. Anthraquinones from *Alternaria* sp.

A list of twenty anthraquinones was isolated earlier from different species of *Alternaria* including the previously mentioned compounds, **100–102**, **104**, **105**, **107**, **108**, and **114** as well as twelve anthraquinone derivatives, **131–142**. Two bioactive bi-anthraquinones, named alterporriol K (**131**) and L (**132**) were isolated from the marine endophytic fungus *Alternaria* sp. ZJ9-6B ref. 98 and displayed moderate cytotoxic activity against the human breast cancer cells, MCF-7 and MDA-MB-435 with IC₅₀ values of [29.11 and 26.97 μM] for alterporriol K (**131**) and [20.04 and 13.11 μM] for alterporriol L (**132**), respectively, while alterporriol M (**133**) was not evaluated for any biological activity in this study.⁹⁸

Further compounds including alterporriol O (**134**) and P (**135**) were isolated from the marine-derived *Aspergillus* sp. ZJ-2008003. Only alterporriol P (**135**) exhibited significant cytotoxicity against the human prostate cancer cell line, PC3, colon cancer cell line, HCT-116, liver hepatoma cell lines, Hep-G2 and Hep-3B in addition to the breast cancer cell line, MCF-7/ADR with IC₅₀ values of 6.4, 8.6, 20.0, 21.0, and 23.0 μM , respectively. Unlikely, alterporriol O (**134**) did not demonstrate any bioactivity when it was evaluated for its cytotoxicity, antibacterial activity, and antiviral activities.⁹³






Fig. 6 Chemical structures of compounds 99–113.

Additional anthraquinones, tetrahydroaltersolanols C–F (136–139) were also isolated from the marine-derived *Alternaria* sp. ZJ-2008003.⁹³ Only tetrahydroaltersolanol C (136) displayed moderate antiviral activity against the porcine reproductive and respiratory syndrome virus with an IC_{50} value of 65.0 μ M.⁹³

More anthraquinone derivatives 140–142 were reported recently from the marine fungus *Alternaria tenuissima* DFFSCS013.⁹⁹ Anthrininone A (140) demonstrated selective protein tyrosine phosphatase inhibitory effect on indoleamine 2,3 dioxygenase 1 enzyme with an IC_{50} value of 32.3 μ M as well as the stimulatory effect on the intracellular levels of calcium in HEK293 cells at a concentration of 10.0 μ M.⁹⁹ It is noteworthy that 6-*O*-methyl-alaternin (141) displayed a wide range of anti-protein tyrosine phosphatases activity including activity against TCPTP, SHP1, SHP2, and PTP-MEG2 enzymes with potent bioactivity against both indoleamine 2,3 dioxygenase 1 enzyme and PTP1B with IC_{50} values of 1.7 and 2.1 μ M, respectively. On the other hand, compound 141 did not show a noticeable stimulatory effect on the intracellular levels of calcium in HEK293 cells at a concentration of 10.0 μ M ref. 99 (Fig. 8).

3.6. Anthraquinones from *Trichoderma* sp.

Trichoderma sp. is another prolific anthraquinones producer from which the previously discussed compounds 14, 83, and 84 were isolated as well as the anthraquinone derivatives, 143–155. Harzianumones A and B (143 and 144) were reported earlier as new hydroxyanthraquinones from the marine fungus *T. harzianum* XS-20090075.¹⁰⁰ They showed neither DNA Topo I inhibitory activity nor anti-acetylcholinesterase activity.¹⁰⁰ The

same study revealed that phomarin (145), ω -hydroxydigitoemodin (146), pachybasin (147), and (+)-2'-*S*-isorhodoptilometrin (148) isolated also from *T. harzianum* XS-20090075, displayed a weak anti-acetylcholinesterase activity at a concentration of 100.0 μ M.¹⁰⁰

Interestingly, pachybasin (147) also demonstrated potent cytotoxic activity against the human cancer cell lines, KB and KBv200 with IC_{50} values of 3.17 and 3.21 μ M, respectively.⁴⁰ In addition, its derivative, ω -hydroxypachybasin (149) as well as (+)-2'-*S*-isorhodoptilometrin (148) exhibited moderate or good cytotoxicity against Hep-G2 and HeLa cancer cell lines showing IC_{50} values of [9.39 and 22.6 μ M] for ω -hydroxypachybasin (149) and [2.10 and 8.59 μ M] for (+)-2'-*S*-isorhodoptilometrin (148), respectively, whilst only ω -hydroxypachybasin (149) exhibited cytotoxicity against the colon cancer cells, HCT-116 with an IC_{50} value of 29.8 μ M.¹⁰⁰ Also, compounds 148 and 149 revealed moderate DNA Topo I inhibitory activity with IC_{50} values of 100.0 and 50.0 μ M, respectively, in addition to moderate selective antibacterial activity against the Gram-positive bacterium, *S. aureus* showing MIC value of 25.0 μ M for both compounds.¹⁰⁰

Moreover, another study demonstrated that compound 148 isolated from the marine-derived fungus *T. aureoviride* PSU-F95 showed good antibacterial activity against MRSA with a MIC value of 16.0 μ g mL⁻¹.⁵⁴ Similarly, coniothranthraquinone 1 (150) displayed significant antibacterial activity against MRSA and *S. aureus* with MIC values of 8.0 and 16 μ g mL⁻¹, respectively.⁵⁴ In the contrast, trichodermaquinone (151) which was also isolated from the marine fungus *T. aureoviride* PSU-F95 demonstrated very weak antibacterial activity against MRSA with a MIC value of 200.0 μ g mL⁻¹.⁵⁴ However, compounds 152 and 153 which






Fig. 7 Chemical structures of compounds 114–130.

were recovered also from the marine fungus *T. aureoviride* PSU-F95, both were not evaluated for any bioactivity in this study.⁵⁴

Additionally, coniothyronone A (154) and lentisone (155) were previously isolated from another marine fungus, *Trichoderma* sp., and exhibited potent antibacterial activity against the Gram-negative bacteria, *V. parahaemolyticus*, *V. anguillarum*, and *Pseudomonas putida* with MIC values of [6.25, 1.56, 3.13 μM] for coniothyronone A (154) and [12.5, 1.56, 6.25 μM] for lentisone (155), respectively⁶⁰ (Fig. 9).

3.7. Anthraquinones from *Eurotium* sp.

Seventeen anthraquinones and their derivatives were reported from species of the marine fungus *Eurotium*, including the previously mentioned compounds 14, 15, 18–20, 60, 62, 97, and 154 in addition to other eight congeners, 156–163. Compound 9-dehydroxyeurotinone (156) and its *O*-methyl derivative, 2-*O*-methyl-9-dehydroxyeurotinone (157) as well as its glycosidic derivative, 2-*O*-methyl-4-*O*-(α -D-ribofuranosyl)-9-dehydroxyeurotinone (158) were isolated from the marine-derived fungus *Eu.*






Fig. 8 Chemical structures of compounds 131–142.

rubrum.^{58,62} The parent compound, 9-dehydroxyeuronone (156) exhibited weak antibacterial activity against the Gram-negative bacterium, *E. coli* showing a 7 mm zone of inhibition using 100.0 μg per disk. Also, it displayed selective cytotoxic activity against the human cholangiocarcinoma cells, SW1990 with an IC_{50} value of 25.0 $\mu\text{g mL}^{-1}$.⁵⁸ Another study revealed that compounds 157–159 had positive antioxidant activity through free radical scavenging activity against DPPH.⁶²

Furthermore, the same study showed that eurorubrin (160) demonstrated a potent free radical scavenging activity with an IC_{50} value of 44.0 μM with better antioxidant activity than the standard antioxidant, butylated hydroxytoluene which had an IC_{50} value of 82.6 μM .⁶² Interestingly, 3-*O*-(α -D-ribofuranosyl)-

questin (159) and eurorubrin (160) were re-isolated also from the marine endophytic fungus *Eu. cristatum* EN 220. They displayed modest antibacterial activity against the Gram-negative bacterium, *E. coli* with MIC values of 32.0 and 64.0 $\mu\text{g mL}^{-1}$, respectively.¹⁰¹ Notably, 3-*O*-(α -D-ribofuranosyl)questinol (161) which is an alcoholic derivative of the bioactive compound, 3-*O*-(α -D-ribofuranosyl)questin (159) showed no antibacterial activity against *E. coli* suggesting that this hydroxylation leads to loss of the antimicrobial activity.¹⁰¹

Furthermore, asperflavin ribofuranoside (162) which was isolated earlier from the marine fungus *Eu. cristatum* EN 220 ref. 101 and the marine-derived fungus *Microsporium* sp.,¹⁰² was reported as a potent free radical scavenging agent with an IC_{50}




Fig. 9 Chemical structures of compounds 143–155.






Fig. 10 Chemical structures of compounds 156–163.

value of 14.2 μM with better antioxidant activity than the standard antioxidant, ascorbic acid which had an IC_{50} value of 20.0 μM .¹⁰² Also, it exhibited modest antibacterial activity against both MRSA and the multidrug-resistant *S. aureus* with MIC values of 50.0 and 50.0 $\mu\text{g mL}^{-1}$, respectively.¹⁰² Moreover, rubrumol (**163**) was reported as a new anthraquinone derivative from the saline-alkali endophytic fungus *Eu. rubrum* with relaxation activity on Topo I with an IC_{50} value of 23.0 μM ¹⁰³ (Fig. 10).

3.8. Anthraquinones from *Fusarium* sp.

Twelve anthraquinone derivatives were isolated earlier from different species of the marine-derived fungus *Fusarium* sp. including the previously discussed compounds 5–8 and 10 along with other structurally related compounds 164–170. Although both nigrosporin A (**164**) and fusaranthraquinone (**165**) were recovered from the marine-derived fungus *Fusarium* sp. PSU-F14,³⁹ only nigrosporin A (**164**) displayed promising inhibitory activity against photosynthesis and weak antibacterial activity against *B. subtilis* showing an inhibition zone of 14 mm at 200 ppm,⁴⁴ whereas fusaranthraquinone (**165**) did not demonstrate any antibacterial activity when it was tested against both *S. aureus* and MRSA.³⁹ Interestingly, additional bioactive fusaquinones A–C (**166–168**) were reported from the marine fungus *Fusarium* sp. ZH-210 and displayed weak

cytotoxic activity against MCF-7, KB, and KBv200 cell lines with IC_{50} values of more than 50.0 μM .¹⁰⁴

It is noteworthy that nigrosporin A (**164**) and fusaquinone A (**166**) were also evaluated in another study for their antimalarial, anti-mycobacterial, antibacterial, and cytotoxic activity. Both compounds showed no antimalarial, antibacterial, or anti-mycobacterial activity, whereas they showed selective cytotoxicity.¹⁰⁵ Nigrosporin A (**164**) displayed weak cytotoxic activity against the MCF-7 cell line with an IC_{50} value of 110.36 μM and good cytotoxicity against the NCI-H187 cell line with an IC_{50} value of 13.69 μM , while fusaquinone A (**166**) exhibited weak cytotoxicity against both human cancer cells, MCF-7, and monkey kidney cells, Vero cells with IC_{50} values of 84.38 and 44.46 μM , respectively. Also, fusaquinone A (**166**) displayed potent cytotoxicity against the NCI-H187 cell line with an IC_{50} value of 7.32 μM .¹⁰⁵ Another bioactive anthraquinone derivative isolated from the mangrove-derived fungus *Fusarium* sp. ZZF60 was 6,8-dimethoxy-1-methyl-2-(3-oxobutyl)anthracene-9,10-dione (**169**).¹⁰⁶ Notably, it demonstrated moderate cytotoxicity against Hep2 and Hep-G2 cells with IC_{50} values of 16.00 and 23.00, respectively (Fig. 11).

3.9. Anthraquinones from *Engyodontium album*

Six compounds 171–176 out of seven anthraquinone derivatives 171–177 isolated from the marine-derived fungus *Engyodontium*




Fig. 11 Chemical structures of compounds 164–170.






Fig. 12 Chemical structures of compounds 171–177.

album LF069 were bioactive, while the anthraquinone derivative, Engyodontochone D (177) was not tested for any relevant biological activity.²³ It is noteworthy that compounds 171–173 exhibited diverse bioactivities including antibacterial, antifungal, and cytotoxic activity. They demonstrated better antibacterial activity against *S. epidermidis* and MRSA than chloramphenicol with an IC_{50} values of [0.19 and 0.17 μM] for engyodontochone A (171), [0.21 and 0.25 μM] for JBIR-99 (172), and [0.22 and 0.24 μM] for engyodontochone B (173), respectively.²³ On the other hand, they displayed weak to modest antifungal activity against the fungi, *C. albicans*, and *T. rubrum* with IC_{50} values ranging from 4.3 to 13.5 μM . Additionally, compounds 171–173 exhibited moderate cytotoxicity against the mouse fibroblasts cell line, NIH-3T3 with IC_{50} values of 11.0, 13.2, and 14.4 μM , respectively.²³

In addition, engyodontochone C (174) in the same study showed a good selective bioactivity against *S. epidermidis* and MRSA with IC_{50} values of 1.80 and 2.39 μM , respectively. In addition, it displayed weak cytotoxic activity against the cell line, NIH-3T3 with an IC_{50} value of 34.3 μM , whereas it did not show any antifungal activity against either, *C. albicans* or *T. rubrum* up to a concentration of 100.0 μM .²³ Similarly, engyodontochone F (175) demonstrated promising selective antibacterial activity against both *S. epidermidis* and MRSA with IC_{50} values of 3.41 and 3.13 μM , respectively although it exhibited weak selective antifungal activity against *T. rubrum* with an IC_{50} value of 73.4 μM . In the contrast, engyodontochone E (176) has only showed potent antibacterial activity against *S. epidermidis* and MRSA with IC_{50} values of 6.77 and 6.74 μM , respectively with no antifungal or cytotoxic activity up to a concentration of 100.0 and 50.0 μM , respectively²³ (Fig. 12).

3.10. Anthraquinones from *Sporendonema casei*

Seven bioactive anthraquinones named 4-dehydroxyaltersolanol A (178) and auxarthrols D–H (179–183) along with the previously discussed altersolanol B (101) were recovered from the marine fungus, *Sporendonema casei* HDN16-802.¹⁰⁷ This group of anthraquinone derivatives 178–183 were evaluated for their antibacterial activity against *M. phlei*, *B. subtilis*, *V. parahaemolyticus*, *E. coli*, *Pseudomonas aeruginosa*, and *Proteus* sp. and for their antifungal activity against *C. albicans*.

Interestingly, 4-dehydroxyaltersolanol A (178) exhibited the best antibacterial activity among this group of anthraquinones against *M. phlei*, *B. subtilis*, *Pseudomonas aeruginosa*, *V. parahaemolyticus*, and *Proteus* sp. with MIC values ranging from 25.0 to 50.0 μM .¹⁰⁷ However, its parent altersolanol A (99) demonstrated potent antibacterial activity against *S. aureus*, *E. coli*, *B. subtilis*, and *Micrococcus tetragenus* with MIC values of 2.07, 4.1, 4.1, and 8.2 μM ,⁹⁰ suggesting that its dehydroxylation might lead to a decrease in its antimicrobial activity.

In the contrast, auxarthrol E (180) and H (183) showed no antimicrobial activity against different indicator strains. However, auxarthrol F (181) only displayed very weak activity against *M. phlei*, *B. subtilis*, *Pseudomonas aeruginosa*, and *Proteus* sp. with a MIC value of 200.0 μM . Both auxarthrol D (179) and G (182) demonstrated a broad spectrum of antibacterial activity against *M. phlei*, *B. subtilis*, *Pseudomonas aeruginosa*, *V. parahaemolyticus*, and *Proteus* sp. with MIC values ranging from 25.0 to 100.0 μM , whereas compound 182 displayed very weak antifungal activity against *C. albicans* with a MIC value of 200.0 μM .¹⁰⁷

Moreover, only compounds 179 and 181 were evaluated for their cytotoxicity against different cancer cell lines in the same study revealing modest cytotoxic activity against several cell lines. Compound 179 exhibited a selective cytotoxic effect on seven cell lines including HL-60, HCT-116, MGC-803, MDA-MB-231, SH-SY5Y, PC-3, and BEL-7402 with IC_{50} values ranging from 7.5 to 22.9 μM . In the contrast, compound 181 displayed a broad spectrum of cytotoxicity against the eleven tested cancer cell lines in this study with IC_{50} values ranging from 4.5 to 22.2 μM .¹⁰⁷ In addition, all compounds 178–183 showed significant anticoagulant activity, meanwhile, they did not show any antimycobacterial activity¹⁰⁷ (Fig. 13).

3.11. Anthraquinones from other marine fungi

A considerable number of anthraquinones and their derivatives were isolated from other marine-derived fungi including compounds 184–208. Compounds 184–192, as well as previously discussed anthraquinone derivatives, 5, 41, 83, and 147, were reported from the mangrove endophytes, *Halorosellinia* sp. No. 1403 and *Guignardia* sp. No. 4382.⁴⁰ Eight compounds from them, 184–191 showed weak cytotoxic activity, while 192






Fig. 13 Chemical structures of compounds 178–183.

displayed no cytotoxicity up to a concentration of 500.0 μM .⁴⁰ It is noteworthy that compounds **184–188** exhibited weak cytotoxicity against both tested cancer cell lines, KB and KBv200 with IC_{50} values ranging from 34.64 to 243.69 μM , whereas compounds **189–191** demonstrated a narrow spectrum of activity against only KBv200 cell line with IC_{50} values of 72.60, 185.68, and 301.47 μM , respectively. The best cytotoxicity was recorded for 1,3-dihydroxy-6-methoxy-8-methyl-anthracene-9,10-dione (**187**) which displayed activity against both KB and KBv200 cells lines with IC_{50} values of 38.05 and 34.64 μM , respectively.⁴⁰

Interestingly, SZ-685C (**193**) was isolated as a novel anthraquinone derivative from the marine endophytic fungus *Halorosellinia* sp. No. 1403 with anticancer potential.^{108–110} It was demonstrated that SZ-685C (**193**) had anticancer activity against the rat pituitary adenoma (MMQ) and human non-functioning pituitary adenoma cell lines with IC_{50} values of 14.51 and 18.76 μM , respectively, while it had an IC_{50} value of 56.09 μM against the normal cell line, rat pituitary cells.¹⁰⁸ Another study revealed similar results of its cytotoxic activity against the MMQ and normal rat pituitary cell lines with IC_{50} values of 13.2 and 49.1 μM , respectively.¹¹⁰ Also, it showed good cytotoxicity against both human MCF-7 and MCF-7/ADR cancer cell lines with IC_{50} values of 7.38 and 4.17 μM , respectively.¹⁰⁹

Additional anthraquinone derivatives, phomopsanthraquinone (**194**), and 1-hydroxy-3-methoxy-6-methyl-anthraquinone (**195**) were isolated from the marine-derived fungus, *Phomopsis* sp. PSU-MA214, besides the previously mentioned compounds **102**, **107**, **108**, and **136**.¹¹¹ Phomopsanthraquinone (**194**) demonstrated cytotoxicity against MCF-7 and KB cancer cell lines with an IC_{50} value of 27.0 $\mu\text{g mL}^{-1}$ for both cell lines. Also, it exhibited moderate antibacterial activity against both MRSA and *S. aureus* with MIC values of 64.0 and 128.0 $\mu\text{g mL}^{-1}$, respectively. In the contrast, 1-hydroxy-3-methoxy-6-methyl-anthraquinone (**195**) neither showed antibacterial activity nor cytotoxicity.¹¹¹

Further three anthraquinones, tetrahydroxyanthraquinone (**196**), methoxy-tetrahydroxyanthraquinone (**197**), and 1,2,3,6,8-pentahydroxy-7-[[1 R)-1-methoxyethyl]-9,10-anthraquinone (**198**) along with previously mentioned noraverufanin (**36**), were recorded from the sponge-associated fungus *Microsphaeropsis* sp.¹¹² All those anthraquinones showed a broad

spectrum of protein kinases' inhibitory activity against cyclin-dependent kinase 4 in complex with its activator cyclin D1, protein kinase C, and epidermal growth factor receptor with IC_{50} values ranging from 18.5 to 54.0 μM .¹¹²

Moreover, the anthraquinone, lunatin (**199**), and the anthraquinone dimer, cytoskyrin A (**200**) were reported earlier from the sponge-associated fungus *Curvularia lunata* with positive antibacterial activity.¹¹³ Both compounds exhibited antibacterial activity against *B. subtilis*, *S. aureus*, and *E. coli* using the disk diffusion method at a concentration of 5.0 μg per disk. Meanwhile, they showed no antifungal activity against *C. albicans* up to a concentration of 10.0 μg per disk.¹¹³

Furthermore, rheomodol (**201**), 2,2'-bis-(7-methyl-1,4,5-trihydroxy-anthracene-9,10-dione) (**202**), as well as the previously discussed compounds **62**, **63**, and **84**, were isolated earlier from another sponge-associated fungus *Talaromyces stipitatus* KUFA 0207.⁸² Rheomodol (**201**) displayed no significant anti-obesity activity, whereas 2,2'-bis-(7-methyl-1,4,5-trihydroxy-anthracene-9,10-dione) (**202**) was not tested for any relevant activity.⁸²

Additional two anthraquinones, 7-methoxymacrosporin (**203**) and 7-(γ,γ)-dimethyl-allyloxy-macrosporin (**204**) along with the previously discussed compounds **102**, **105**, **107** and **108**, were isolated from the mangrove fungus, *Phoma* sp. L28.⁹¹ 7-methoxymacrosporin (**203**) displayed weak antifungal activity against *F. graminearum*, *F. oxysporum*, *P. italicum*, *Rhizoctonia solani*, and *Colletotrichum gloeosporioides* with MIC values of 100.0, 100.0, 100.0, 150.0, and 200.0 $\mu\text{g mL}^{-1}$, respectively. Also, 7-(γ,γ)-dimethyl-allyloxy-macrosporin (**204**) demonstrated weak selective antifungal activity against *F. graminearum*, *Rhizoctonia solani*, and *Colletotrichum gloeosporioides* with MIC values of 80.0, 150.0, and 200.0 $\mu\text{g mL}^{-1}$, respectively.⁹¹ By comparing this weak antifungal activity of **203** and **204** to their parent macrosporin (**108**) which displayed potent antifungal activity against *F. oxysporum* and modest antifungal activity against *Colletotrichum musae*, *F. graminearum*, *P. italicum*, and *Colletotrichum gloeosporioides*,⁹¹ we can conclude that the structural modifications in both **203** and **204** have greatly affected their bioactivity.

Four additional bioactive anthraquinone derivatives were reported from the marine-derived fungus *Monodictys* sp. including the previously discussed compounds **14**, **83**, and **147**






Fig. 14 Chemical structures of compounds 184–208.

as well as monodictyquinone A (**205**). Compound **205** displayed promising antimicrobial activity against *B. subtilis*, *E. coli*, and *C. albicans* showing zones of inhibition with a diameter of 15.0, 15.0, and 11.0 mm, respectively at a concentration of 10.0 μg per disk.⁵⁵

Two other anthraquinone derivatives, 1,3,6-trihydroxy-7-(1-hydroxyethyl) anthracene-9,10-dione (**206**) and phaseolorin I (**207**) were isolated earlier from the marine-derived fungi, *Cladosporium* sp. HNWSW-1 ref. 114 and *Diaporthe phaseolorum* FS431,¹¹⁵ respectively. Phaseolorin I (**207**) was inactive when it was tested for its cytotoxicity against the cell lines, MCF-7, Hep-G2, A549, and SF-268,¹¹⁵ whereas compound **206** did not demonstrate cytotoxicity against the cell lines, BEL-7042, HeLa, and K562 as well as the human papillomavirus-related endocervical adenocarcinoma SGC-7901 cell lines.¹¹⁴ However, anthraquinone **206** exhibited α -glycosidase inhibitory activity with an IC_{50} value of 49.3 μM compared to the standard agent, acarbose which had an IC_{50} value of 275.7 μM .¹¹⁴

Finally, 6,8-*O,O'*-dimethyl-averufanin (**208**) which is a derivative of the bioactive anthraquinone derivative, averufanin (**35**) was previously reported from the unidentified marine endophytic fungus ZSUH-36 as well as the previously mentioned compounds **27**, **30**, **32** and **33**, **40**, **43**, and **80**.¹¹⁶ Compound **208**

demonstrated weak antifungal activity against the phytopathogenic fungi, *Botrytis cinerea* and *Magnaporthe oryzae* with MIC values of 50.0 and 100.0 μM , respectively.¹¹⁷ Also, it displayed good phytotoxicity on the hypocotyls of radish seedlings at a concentration of 100.0 μM with an inhibition rate of 30.6% compared to 28.1% for the standard, glyphosate¹¹⁷ (Fig. 14).

4 Drug likeness and pharmacokinetics of marine anthraquinones

Altogether, **208** anthraquinones and their derivatives were characterized from 20 marine-derived fungal genera. These include *Nigrospora*, *Aspergillus*, *Penicillium*, *Stemphylium*, and *Alternaria*, among others. The identified anthraquinones revealed diverse biological and pharmacological activities including anticancer, antiviral, antimicrobial, antioxidant, and anti-inflammatory activities. Here, we attempted to highlight their potential as drug candidates *via* exploring their drug-likeness using several molecular descriptors including several drug-likeness rules (Muegge, Ghose, Veber, Egan, and Lipinski). Surprisingly, **133** anthraquinones satisfied all parameters of the






Fig. 15 Distribution of molecular weight (M_{wt}), fraction of sp^3 carbons (FC_{sp^3}), number of rotatable bonds (RB), topological polar surface area (TPSA), lipophilicity ($\log P$), solubility ($\log S$) according to the species. Comparison between the values of FC_{sp^3} and M_{wt} , $\log P$ and M_{wt} , TPSA and M_{wt} , $\log S$ and M_{wt} , $\log P$ and $\log S$, and $\log S$ and TPSA. NIG: *Nigrospora* sp., ASP: *Aspergillus* sp., PEN: *Penicillium* sp., STE: *Stemphylium* sp., ALT: *Alternaria* sp., TRI: *Trichoderma* sp., EUR: *Eurotium* sp., FUS: *Fusarium* sp., ENG: *Engyodontium album*, SPO: *Sporendonema casei*, and OTH: other marine fungi.






Fig. 16 Heatmap of the compliance with rules of drug-likeness according to the classes. LIP: Lipinski, GHO: Ghoose, VEB: Veber, EGA: Agan and MUE: Muegge. NIG: *Nigrospora* sp., ASP: *Aspergillus* sp., PEN: *Penicillium* sp., STE: *Stemphylium* sp., ALT: *Alternaria* sp., TRI: *Trichoderma* sp., EUR: *Eurotium* sp., FUS: *Fusarium* sp., ENG: *Engyodontium album*, SPO: *Sporendonema casei*, and OTH: other marine fungi.

Table 1 Anthraquinones and their derivatives isolated from different species of marine-derived fungi with their sources and biological activities. MF = Molecular formula

| Compound | MF | Name | Bioactivity | Source | Ref. |
|----------|---|---|---|--|-------------------|
| 1 | C ₃₁ H ₃₂ O ₁₂ | Nigrodiquinone A | Displayed no antibacterial or antiviral activity | Zoanthid-derived fungus <i>Nigrospora</i> sp. | 37 |
| 2 | C ₁₇ H ₂₂ O ₇ | 4a- <i>epi</i> -9-methoxydihydrodeoxybostrycin | Antibacterial activity | Zoanthid-derived fungus <i>Nigrospora</i> sp. and sea anemone-derived fungus <i>Nigrospora</i> sp. | 37 and 38 |
| 3 | C ₁₆ H ₁₆ O ₇ | 10-Deoxybostrycin | Antibacterial and cytotoxic activities | Zoanthid-derived fungus <i>Nigrospora</i> sp. and sea anemone-derived fungus <i>Nigrospora</i> sp. | 37 and 38 |
| 4 | C ₁₆ H ₁₂ O ₆ | 3,5,8-Trihydroxy-7-methoxy-2-methyl-anthracene-9,10-dione | Antiviral activity | Zoanthid-derived fungus <i>Nigrospora</i> sp. and sea anemone-derived fungus <i>Nigrospora</i> sp. | 37 and 38 |
| 5 | C ₁₆ H ₁₂ O ₅ | Austrocortirubin | Antiviral and cytotoxic activities | Zoanthid-derived fungus <i>Nigrospora</i> sp., mangrove endophytic fungi <i>Halorosellinia</i> sp. (no. 1403), and <i>Guignardia</i> sp. (no. 4382), sea anemone-derived fungus <i>Nigrospora</i> sp., and sea fan-derived fungi <i>Fusarium</i> sp. PSU-F14 | 37–41 |
| 6 | C ₁₆ H ₁₆ O ₆ | Nigrosporin B | Antibacterial, anti-mycobacterial, cytotoxic, and phytotoxic activities | Sea anemone-derived fungus <i>Nigrospora</i> sp. and sea fan-derived fungi <i>Fusarium</i> sp. PSU-F14 | 38, 39, 43 and 44 |
| 7 | C ₁₆ H ₂₀ O ₇ | 1-Deoxytetrahydrobostrycin | Antibacterial and cytotoxic activities | Sea anemone-derived fungus <i>Nigrospora</i> sp., sea fan-derived fungi <i>Fusarium</i> sp. PSU-F14 and marine-derived fungus <i>Aspergillus</i> sp. | 38, 39, 42 |
| 8 | C ₁₆ H ₂₀ O ₈ | Tetrahydrobostrycin | Antibacterial, antimalarial, anti-mycobacterial, and cytotoxic activities | Sea anemone-derived fungus <i>Nigrospora</i> sp., sea fan-derived fungi <i>Fusarium</i> sp. PSU-F14, and marine-derived fungus <i>Aspergillus</i> sp. | 38, 39, 42 and 46 |
| 9 | C ₁₆ H ₁₆ O ₇ | 4-Deoxybostrycin | Antibacterial, anti-mycobacterial, and cytotoxic activities | Sea anemone-derived fungus <i>Nigrospora</i> sp. | 38, 43 and 45 |
| 10 | C ₁₆ H ₁₆ O ₈ | Bostrycin | Antibacterial, antimalarial, and cytotoxic activities | Sea anemone-derived fungus <i>Nigrospora</i> sp., sea fan-derived fungi <i>Fusarium</i> sp. PSU-F14, and marine-derived fungus <i>Aspergillus</i> sp. | 38, 39, 42 and 45 |
| 11 | C ₂₅ H ₁₆ O ₉ | Aspergiolide A | Cytotoxic activity | Marine-derived fungus <i>A. glaucus</i> | 47 and 48 |
| 12 | C ₂₆ H ₁₈ O ₉ | Aspergiolide B | Cytotoxic activity | Marine-derived fungus <i>A. glaucus</i> | 47 |



Table 1 (Contd.)

| Compound MF | Name | Bioactivity | Source | Ref. | |
|-------------|---|--|--|--|-----------------------------|
| 13 | C ₁₆ H ₁₂ O ₅ | Physcion | Antifungal, antioxidant, and cytotoxic activities | Marine-derived fungi <i>Microsporium</i> sp., <i>A. glaucus</i> , and halotolerant <i>A. varicolor</i> , and marine algae-derived fungus <i>A. wentii</i> EN-48 | 47 and 49–52 |
| 14 | C ₁₅ H ₁₀ O ₅ | Emodin | Antibacterial, antifungal, anti-HCV protease, anti-mycobacterial, and cytotoxic activities | Sea fan-derived fungus <i>P. citrinum</i> PSU-F51, marine-derived fungi <i>T. aureoviride</i> PSU-F95, <i>Trichoderma</i> sp., <i>A. glaucus</i> , and halotolerant <i>A. varicolor</i> , marine lichen-derived fungus <i>Gliocladium</i> sp. T31, sea urchin-derived fungus <i>Monodictys</i> sp., marine mangrove fungus <i>Paecilomyces</i> sp., and marine-derived endophytic fungus <i>Eu. rubrum</i> | 40, 47, 50, 53–61 and 63 |
| 15 | C ₁₆ H ₁₆ O ₅ | Asperflavin | Antioxidant activity | Marine-derived fungus <i>A. glaucus</i> and marine algae-derived endophytic fungus <i>Eu. cristatum</i> EN-220 | 47, 62 and 101 |
| 16 | C ₁₆ H ₁₆ O ₅ | Isoasperflavin | Displayed no cytotoxic activity | Marine-derived fungus <i>A. glaucus</i> | 47 |
| 17 | C ₁₆ H ₁₂ O ₅ | Questin | Antioxidant activity | Marine-derived fungi <i>A. glaucus</i> and halotolerant <i>A. varicolor</i> , and mangrove-derived fungus <i>P. citrinum</i> HL-5126 | 47, 50, 62 and 84 |
| 18 | C ₁₅ H ₁₀ O ₆ | Catenarin | Antibacterial activity | Marine-derived fungi <i>A. glaucus</i> , <i>Eu. Rubrum</i> , and halotolerant <i>A. varicolor</i> | 47, 50, 63 and 103 |
| 19 | C ₁₆ H ₁₂ O ₆ | Rubrocristin | Displayed no antibacterial activity | Marine-derived fungi <i>A. glaucus</i> , <i>Eu. Rubrum</i> , and halotolerant <i>A. varicolor</i> | 47, 50, 63 and 103 |
| 20 | C ₂₀ H ₁₈ O ₁₀ | (+)-variecolorquinone A | Cytotoxic activity | Marine-derived fungi <i>A. glaucus</i> and halotolerant <i>A. varicolor</i> , and marine algae-derived endophytic fungus <i>Eu. cristatum</i> EN-220 | 47, 50 and 101 |
| 21 | C ₃₂ H ₂₆ O ₈ | Physcion-10,10'-bianthrone | Was not evaluated for any relevant bioactivity | Marine-derived fungus <i>A. glaucus</i> | 47 |
| 22 | C ₃₁ H ₂₄ O ₈ | (<i>trans</i>)-emodin-physcion bianthrone | Cytotoxic activity | Marine-derived fungus <i>A. glaucus</i> | 47 |
| 23 | C ₃₁ H ₂₄ O ₈ | (<i>cis</i>)-emodin-physcion bianthrone | Cytotoxic activity | Marine-derived fungus <i>A. glaucus</i> | 47 |
| 24 | C ₄₂ H ₄₂ O ₁₃ | 6,6'-oxybis(1,3,8-trihydroxy-2-((S)-1-methoxyhexyl)anthracene-9,10-dione) | Antibacterial and cytotoxic activities | Marine-derived fungus <i>A. versicolor</i> | 64 |
| 25 | C ₄₀ H ₃₈ O ₁₃ | 6,6'-oxybis(1,3,8-trihydroxy-2-((S)-1-hydroxyhexyl) anthracene-9,10-dione) | Antibacterial activity | Marine-derived fungus <i>A. versicolor</i> | 64 |
| 26 | C ₂₀ H ₂₀ O ₇ | Averantin | Antibacterial, antioxidant, and cytotoxic activities | Marine-derived fungi <i>A. versicolor</i> and <i>P. purpurogenum</i> G59 | 64, 65, 67, 68 and 118 |
| 27 | C ₂₁ H ₂₂ O ₇ | 1'- <i>O</i> -methyl-averantin | Antibacterial, antioxidant, and cytotoxic activities | Marine-derived fungi <i>A. versicolor</i> and <i>P. purpurogenum</i> G59, and the mangrove endophytic fungus (ZSUH-36) | 64, 65, 67, 68 and 116 |
| 28 | C ₂₀ H ₁₈ O ₆ | Averythrin | Antioxidant and cytotoxic activities | Marine-derived fungi <i>A. versicolor</i> and <i>Aspergillus</i> sp. SCSIO F063 | 64, 66 and 67 |
| 29 | C ₂₂ H ₂₄ O ₇ | 6,8- <i>O,O'</i> -dimethyl-averantin | Antibacterial activity | Marine-derived fungus <i>A. versicolor</i> EN-7 | 69 |
| 30 | C ₂₀ H ₁₆ O ₇ | Averufin | Antibacterial, antioxidant, antiviral, and cytotoxic activities | Marine-derived fungi <i>A. versicolor</i> and <i>A. niger</i> (MF-16), mangrove endophytic fungi ZSUH-36 and (isolate 1850), and mangrove-derived endophytic fungus <i>A. nidulans</i> MA-143 | 67, 68, 70, 71, 116 and 119 |
| 31 | C ₂₁ H ₁₈ O ₇ | 6- <i>O</i> -methyl-averufin | Displayed no antimicrobial activity | Marine-derived fungus <i>A. versicolor</i> EN-7 | 69 |
| 32 | C ₂₂ H ₂₀ O ₇ | 6,8- <i>O,O'</i> -dimethyl-averufin | Displayed no anti-neuroinflammatory activity | Marine-derived fungi <i>Aspergillus</i> sp. SF-6796 and <i>A. versicolor</i> EN-7, and the mangrove endophytic fungus (ZSUH-36) | 69, 72 and 116 |
| 33 | C ₁₈ H ₁₂ O ₇ | Versicolorin B | Antioxidant activity | Marine-derived fungus <i>A. versicolor</i> and mangrove endophytic fungus ZSUH-36 | 67 |



Table 1 (Contd.)

| Compound MF | Name | Bioactivity | Source | Ref. | |
|-------------|--|---|--|---|------------------------|
| 34 | C ₁₈ H ₁₂ O ₈ | 1'-Hydroxyversicolorin B | Antioxidant and cytotoxic activities | Marine-derived fungus <i>A. versicolor</i> | 67 and 74 |
| 35 | C ₂₀ H ₁₈ O ₇ | Averufanin | Antioxidant activity and inhibitory activity of acyl-CoA: Cholesterol acyltransferase | Marine-derived fungus <i>A. versicolor</i> and mangrove-derived endophytic fungus <i>A. nidulans</i> MA-143 | 67 and 75 |
| 36 | C ₁₉ H ₁₆ O ₇ | Noraverufanin | Anti-HIV activity | Sponge-associated fungi <i>Microsphaeropsis</i> sp. and <i>A. versicolor</i> SCSIO 41016 | 73 and 112 |
| 37 | C ₂₀ H ₁₆ O ₈ | Nidurufin | Antibacterial, antioxidant, antiviral, and cytotoxic activities | Marine-derived fungi <i>A. versicolor</i> , <i>A. niger</i> (MF-16), and <i>P. purpurogenum</i> G59, and marine-derived mangrove endophytic fungus (isolate 1850) | 65, 67, 68, 70 and 119 |
| 38 | C ₂₂ H ₂₀ O ₈ | 6,8- <i>O,O'</i> -dimethyl-nidurufin | Antibacterial activity | Marine-derived fungus <i>A. versicolor</i> EN-7 | 69 |
| 39 | C ₁₈ H ₁₆ O ₈ | Versiconol | Cytotoxic activity | Marine-derived fungus <i>A. versicolor</i> | 68 |
| 40 | C ₂₀ H ₂₀ O ₈ | 6,8- <i>O,O'</i> -dimethyl-versiconol | Antibacterial activity | Mangrove endophytic fungus (ZSUH-36) and marine-derived fungus <i>A. versicolor</i> EN-7 | 69 and 120 |
| 41 | C ₁₆ H ₁₂ O ₅ | 1-Methyl-emodin | Anti-HCV protease and cytotoxic activities | Mangrove endophytic fungi <i>Halorosellinia</i> sp. (no. 1403) and <i>Guignardia</i> sp. (no. 4382), and red sea endophytic fungus <i>A. versicolor</i> | 40 and 76 |
| 42 | C ₁₈ H ₁₆ O ₆ | Isorhodoptilometrin-1-methyl-ether | Antibacterial and cytotoxic activities | Red sea endophytic fungus <i>A. versicolor</i> | 76 |
| 43 | C ₂₀ H ₁₆ O ₇ | Aversin | Displayed no antimicrobial activity | Mangrove endophytic fungus (ZSUH-36) and marine-derived fungus <i>A. versicolor</i> EN-7 | 69 and 120 |
| 44 | C ₂₀ H ₁₄ O ₇ | 6,8- <i>O,O'</i> -dimethyl-versicolorin A | Displayed no antimicrobial activity | Marine-derived fungus <i>A. versicolor</i> EN-7 | 69 |
| 45 | C ₁₆ H ₁₂ O ₆ | Evariquinone | Was not evaluated for any relevant bioactivity | Red sea endophytic fungus <i>A. versicolor</i> | 76 |
| 46 | C ₁₇ H ₁₄ O ₆ | 7-Hydroxyemodin 6,8-methyl-ether | Was not evaluated for any relevant bioactivity | Red sea endophytic fungus <i>A. versicolor</i> | 76 |
| 47 | C ₁₅ H ₁₀ O ₃ | 1-Hydroxy-2-methyl-anthraquinone | Anti-mosquito activity | Marine-derived fungus <i>A. versicolor</i> | 59 and 77 |
| 48 | C ₁₇ H ₁₄ O ₅ | 2-(Dimethoxy methyl)-1-hydroxy-9,10-anthraquinone | Antibacterial activity | Marine-derived fungus <i>A. versicolor</i> | 59 |
| 49 | C ₁₅ H ₁₀ O ₂ | Tectoquinone | Was not evaluated for any relevant bioactivity | Marine-derived fungus <i>A. versicolor</i> | 59 |
| 50 | C ₁₆ H ₁₀ O ₅ | Damnacanthal | Antibacterial and anti-mosquito activities | Marine-derived fungus <i>A. versicolor</i> | 59 and 77 |
| 51 | C ₁₄ H ₈ O ₄ | Xanthopurpurin | Antibacterial and anti-platelets aggregation activities | Marine-derived fungus <i>A. versicolor</i> | 59 and 78 |
| 52 | C ₁₅ H ₁₀ O ₄ | Rubiadin | Inhibitory activity on formation of advanced glycation end products | Marine-derived fungus <i>A. versicolor</i> | 59 and 79 |
| 53 | C ₁₅ H ₁₀ O ₅ | 6-Hydroxyrubiadin | Inhibitory effects on the release of β-hexosaminidase and inhibitory activity on phosphatase of regenerating liver-3 | Marine-derived fungus <i>A. versicolor</i> | 59 and 80 |
| 54 | C ₁₆ H ₁₂ O ₅ | Rubianthraquinone | Anti-inflammatory activity | Marine-derived fungus <i>A. versicolor</i> | 59 and 121 |
| 55 | C ₁₆ H ₁₂ O ₇ | Wentiquinone C | Displayed no antioxidant activity | Marine algae-derived fungus <i>A. wentii</i> EN-48 | 49 |
| 56 | C ₁₅ H ₁₀ O ₅ | Alatinone | Was not evaluated for any relevant bioactivity | Marine-derived endophytic fungus <i>A. wentii</i> pt-1 | 81 |
| 57 | C ₁₇ H ₁₄ O ₅ | 5-Hydroxy-1,3-dimethoxy-7-methyl-anthraquinone | Was not evaluated for any relevant bioactivity | Marine-derived endophytic fungus <i>A. wentii</i> pt-1 | 81 |
| 58 | C ₁₆ H ₁₂ O ₅ | 1,5-Dihydroxy-3-methoxy-7-methyl-anthraquinone | Was not evaluated for any relevant bioactivity | Marine-derived endophytic fungus <i>A. wentii</i> pt-1 | 81 |
| 59 | C ₁₅ H ₁₂ O ₆ | Eurotinone | Antioxidant activity and kinase insert domain receptor inhibitory activity | Marine-derived halotolerant fungus <i>A. varicolor</i> | 50 and 122 |



Table 1 (Contd.)

| Compound MF | Name | Bioactivity | Source | Ref. | |
|-------------|--|---|--|--|-----------------------|
| 60 | C ₁₆ H ₁₄ O ₆ | 2-O-methyl-eurotinone | Antioxidant activity | Marine mangrove-derived endophytic fungus <i>Eu. rubrum</i> and marine-derived halotolerant fungus <i>A. varicolor</i> | 50 and 62 |
| 61 | C ₁₉ H ₁₆ O ₉ | (2 <i>S</i>)-2,3-dihydroxypropyl 1,6,8-trihydroxy-3-methyl-9,10-dioxo-9,10-dihydro-2-anthracenecarboxylate | Was not evaluated for any relevant bioactivity | Marine-derived halotolerant fungus <i>A. varicolor</i> | 50 |
| 62 | C ₁₆ H ₁₂ O ₆ | Questinol | Anti-inflammatory and anti-obesity activities | Marine-derived halotolerant fungus <i>A. varicolor</i> and marine-derived fungi <i>Eu. amstelodami</i> and <i>Talaromyces stipitatus</i> KUFA 0207 | 50, 82 and 83 |
| 63 | C ₁₆ H ₁₂ O ₆ | Fallacinol | Displayed no significant anti-obesity activity | Marine-derived halotolerant fungus <i>A. varicolor</i> and marine algae-derived fungus <i>Talaromyces stipitatus</i> KUFA 0207 | 50 and 82 |
| 64 | C ₁₆ H ₁₂ O ₆ | Erythroglaucin | Displayed no antibacterial activity | Marine-derived halotolerant fungus <i>A. varicolor</i> | 50 and 63 |
| 65 | C ₁₈ H ₁₂ O ₇ | Versicolorin C | Antibacterial activity | Marine-derived mangrove endophytic fungus (isolate 1850) and mangrove-derived endophytic fungus <i>A. nidulans</i> MA-143 | 71 and 119 |
| 66 | C ₁₈ H ₁₂ O ₇ | Isoversicolorin C | Antibacterial activity | Mangrove-derived endophytic fungus <i>A. nidulans</i> MA-143 | 71 |
| 67 | C ₂₀ H ₁₈ O ₇ | Norsolorinic acid | Was not evaluated for any relevant bioactivity | Mangrove-derived endophytic fungus <i>A. nidulans</i> MA-143 | 71 |
| 68 | C ₂₁ H ₂₂ O ₇ | (1' <i>S</i>) 6- <i>O</i> -methyl-averantin | Displayed no cytotoxic activity | Marine-derived fungus <i>Aspergillus</i> sp. SCSIO F063 | 66 |
| 69 | C ₂₂ H ₂₄ O ₇ | (1' <i>S</i>) 6,1'- <i>O,O'</i> -dimethyl-averantin | Displayed no cytotoxic activity | Marine-derived fungus <i>Aspergillus</i> sp. SCSIO F063 | 66 |
| 70 | C ₂₄ H ₂₈ O ₇ | Averantin-1'-butyl ether | Cytotoxic activity | Marine-derived fungus <i>Aspergillus</i> sp. SCSIO F063 | 66 |
| 71 | C ₂₀ H ₁₉ ClO ₇ | (1' <i>S</i>)-7-chloroaverantin | Cytotoxic activity | Marine-derived fungus <i>Aspergillus</i> sp. SCSIO F063 | 66 |
| 72 | C ₂₁ H ₂₁ ClO ₇ | (1' <i>S</i>) 6- <i>O</i> -methyl-7-chloroaverantin | Cytotoxic activity | Marine-derived fungus <i>Aspergillus</i> sp. SCSIO F063 | 66 |
| 73 | C ₂₁ H ₂₁ ClO ₇ | (1' <i>S</i>) 1'- <i>O</i> -methyl-7-chloroaverantin | Cytotoxic activity | Marine-derived fungus <i>Aspergillus</i> sp. SCSIO F063 | 66 |
| 74 | C ₂₂ H ₂₃ ClO ₇ | (1' <i>S</i>) 6,1'- <i>O,O'</i> -dimethyl-7-chloroaverantin | Displayed no cytotoxic activity | Marine-derived fungus <i>Aspergillus</i> sp. SCSIO F063 | 66 |
| 75 | C ₂₄ H ₂₇ ClO ₇ | (1' <i>S</i>) 7-chloroaverantin-1'-butyl ether | Cytotoxic activity | Marine-derived fungus <i>Aspergillus</i> sp. SCSIO F063 | 66 |
| 76 | C ₂₀ H ₁₇ ClO ₆ | 7-Chloroaverythrin | Displayed no cytotoxic activity | Marine-derived fungus <i>Aspergillus</i> sp. SCSIO F063 | 66 |
| 77 | C ₂₁ H ₁₉ ClO ₆ | 6- <i>O</i> -methyl-7-chloroaverythrin | Cytotoxic activity | Marine-derived fungus <i>Aspergillus</i> sp. SCSIO F063 | 66 |
| 78 | C ₂₁ H ₂₁ ClO ₆ | (1' <i>S</i>) 6- <i>O</i> -methyl-7-bromoaverantin | Cytotoxic activity | Marine-derived fungus <i>Aspergillus</i> sp. SCSIO F063 | 66 |
| 79 | C ₂₂ H ₂₃ BrO ₇ | (1' <i>S</i>) 6,1'- <i>O,O'</i> -dimethyl-7-bromoaverantin | Displayed no cytotoxic activity | Marine-derived fungus <i>Aspergillus</i> sp. SCSIO F063 | 66 |
| 80 | C ₂₃ H ₂₆ O ₇ | 6,8,1'- <i>O,O',O''</i> -trimethyl-averantin | Anti-inflammatory activity | Marine-derived fungus <i>Aspergillus</i> sp. SF-6796 and mangrove endophytic fungus ZSUH-36 | 72 and 116 |
| 81 | C ₂₈ H ₂₄ O ₁₀ | Penicillanthranin A | Antibacterial and cytotoxic activities | Sea fan-derived fungus <i>P. citrinum</i> PSU-F51 | 53 |
| 82 | C ₂₈ H ₂₄ O ₁₁ | Penicillanthranin B | Displayed no cytotoxic activity | Sea fan-derived fungus <i>P. citrinum</i> PSU-F51 | 53 |
| 83 | C ₁₅ H ₁₀ O ₄ | Chrysophanol | Anti-acetylcholinesterase, antibacterial, and cytotoxic activities | Sea fan-derived fungus <i>P. citrinum</i> PSU-F51, marine-derived fungi <i>T. aureoviride</i> PSU-F95 and <i>Trichoderma</i> sp., mangrove endophytic fungi <i>Halorosellinia</i> sp. (no. 1403) and <i>Guignardia</i> sp. (no. 4382), sea urchin-derived fungus <i>Monodictys</i> sp., and marine mangrove fungus <i>Paecilomyces</i> sp. | 40, 53–55, 57 and 100 |



Table 1 (Contd.)

| Compound MF | Name | Bioactivity | Source | Ref. | |
|-------------|---|---|---|---|----------------------------|
| 84 | C ₁₅ H ₁₀ O ₆ | ω-hydroxyemodin | Antibacterial, anti-mycobacterial, anti-obesity, and cytotoxic activities | Sea fan-derived fungus <i>P. citrinum</i> PSU-F51, mangrove-derived fungus <i>P. citrinum</i> HL-5126, marine-derived fungi <i>T. aureoviride</i> PSU-F95, and <i>Talaromyces stipitatus</i> KUFA 0207, and marine lichen-derived fungus <i>Gliocladium</i> sp. T31 | 53, 54, 56, 61, 82 and 84 |
| 85 | C ₁₈ H ₁₃ ClO ₇ | 2'-Acetoxy-7-chlorocitreosein | Antibacterial activity | Mangrove-derived fungus <i>P. citrinum</i> HL-5126 | 84 |
| 86 | C ₁₅ H ₁₀ O ₉ S | Citreoresein-3-O-sulphate | Was not evaluated for any relevant bioactivity | Marine-derived fungus <i>P. oxalicum</i> 2HL-M-6 | 85 |
| 87 | C ₁₅ H ₁₀ O ₈ S | Emodin-3-O-sulphate | Was not evaluated for any relevant bioactivity | Marine-derived fungus <i>P. oxalicum</i> 2HL-M-6 | 85 |
| 88 | C ₁₅ H ₁₀ O ₅ | Aloe-emodin | Antibacterial and antimalarial activities | Marine-derived fungus <i>P. oxalicum</i> 2HL-M-6 | 85–87 |
| 89 | C ₂₁ H ₁₉ NO ₈ | Emodacidamide A | Immunomodulatory activity | Marine-derived fungus <i>Penicillium</i> sp. SCSIO sof101 | 88 |
| 90 | C ₂₀ H ₁₇ NO ₈ | Emodacidamide B | Immunomodulatory activity | Marine-derived fungus <i>Penicillium</i> sp. SCSIO sof101 | 88 |
| 91 | C ₂₀ H ₁₆ ClNO ₈ | Emodacidamide C | Immunomodulatory activity | Marine-derived fungus <i>Penicillium</i> sp. SCSIO sof101 | 88 |
| 92 | C ₂₂ H ₂₁ NO ₈ | Emodacidamide D | Immunomodulatory activity | Marine-derived fungus <i>Penicillium</i> sp. SCSIO sof101 | 88 |
| 93 | C ₂₁ H ₁₉ NO ₈ | Emodacidamide E | Immunomodulatory activity | Marine-derived fungus <i>Penicillium</i> sp. SCSIO sof101 | 88 |
| 94 | C ₂₁ H ₁₈ ClNO ₈ | Emodacidamide F | Immunomodulatory activity | Marine-derived fungus <i>Penicillium</i> sp. SCSIO sof101 | 88 |
| 95 | C ₂₁ H ₁₈ ClNO ₈ | Emodacidamide G | Immunomodulatory activity | Marine-derived fungus <i>Penicillium</i> sp. SCSIO sof101 | 88 |
| 96 | C ₁₈ H ₁₃ NO ₈ | Emodacidamide H | Immunomodulatory activity | Marine-derived fungus <i>Penicillium</i> sp. SCSIO sof101 | 88 |
| 97 | C ₁₅ H ₈ O ₇ | Emodic acid | Inhibitory activity on tyrosine kinase proteins | Marine-derived endophytic fungus <i>Eu. rubrum</i> and marine-derived fungus <i>Penicillium</i> sp. SCSIO sof101 | 58, 88 and 89 |
| 98 | C ₁₅ H ₉ ClO ₆ | 2-Chloro-1,3,8 trihydroxy-6 (hydroxymethyl)-anthracene-9,10 dione | Immunomodulatory activity | Marine-derived fungus <i>Penicillium</i> sp. SCSIO sof101 | 88 |
| 99 | C ₁₆ H ₁₆ O ₈ | Altersolanol A | Antibacterial and cytotoxic activities, as well as protein kinase inhibitory activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 and coral-associated fungus <i>Stemphylium lycopersici</i> | 90, 92 and 94 |
| 100 | C ₁₆ H ₁₈ O ₇ | Dihydroaltersolanol A | Displayed no antibacterial or cytotoxic activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231, deep-sea-derived fungus <i>Alternaria tenuissima</i> DFFSCS013, and soft coral-derived <i>Alternaria</i> sp. ZJ-2008003 | 90, 93, 99 |
| 101 | C ₁₆ H ₁₆ O ₆ | Altersolanol B | Antibacterial, anticoagulant, anti-mycobacterial, and cytotoxic activities | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231, mangrove endophytic fungus <i>Alternaria</i> sp. ZJ9-6B, coral-associated fungus <i>Stemphylium lycopersici</i> and <i>Alternaria</i> sp. ZJ-2008003, deep sea-derived fungus <i>Alternaria tenuissima</i> DFFSCS013 and marine-derived fungus <i>Sporendonema casei</i> HDN16-802 | 90, 92, 93, 98, 99 and 107 |
| 102 | C ₁₆ H ₂₀ O ₆ | Tetrahydroaltersolanol B | Antibacterial and antifungal activities | Mangrove-derived fungi <i>Phomopsis</i> sp. PSU-MA214, <i>Stemphylium</i> sp. 33 231, and <i>Phoma</i> sp. L28, mangrove endophytic and soft coral-derived <i>Alternaria</i> sp. ZJ9-6B, and soft coral-derived <i>Alternaria</i> sp. ZJ-2008003 | 111 |
| 103 | C ₁₈ H ₁₈ O ₇ | 2-O-acetylaltersolanol B | Antibacterial activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 |
| 104 | C ₁₆ H ₁₆ O ₇ | Altersolanol C | Antibacterial activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 and soft coral-derived <i>Alternaria</i> sp. ZJ-2008003 | 90 and 93 |



Table 1 (Contd.)

| Compound MF | Name | Bioactivity | Source | Ref. | |
|-------------|--|--|--|---|------------------------|
| 105 | C ₁₆ H ₂₀ O ₇ | Altersolanol L | Antifungal and cytotoxic activities | Mangrove-derived fungi <i>Stemphylium</i> sp. 33 231 and <i>Phoma</i> sp. L28, and deep-sea derived fungus <i>Alternaria tenuissima</i> DFFSCS013 and soft coral-derived <i>Alternaria</i> sp. ZJ-2008003 | 90, 91, 93, 99 and 123 |
| 106 | C ₁₈ H ₂₂ O ₈ | 2-O-acetylaltersolanol L | Displayed no antibacterial or cytotoxic activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 |
| 107 | C ₁₆ H ₂₀ O ₈ | Ampelanol | Cytotoxic activity | Mangrove-derived fungi <i>Phomopsis</i> sp. PSU-MA214, <i>Stemphylium</i> sp. 33 231, and <i>Phoma</i> sp. L28, coral-associated fungus <i>Stemphylium lycopersici</i> and <i>Alternaria</i> sp. ZJ-2008003 and, deep-sea derived fungus <i>Alternaria tenuissima</i> DFFSCS013 | 90–94, 99 and 111 |
| 108 | C ₁₆ H ₁₂ O ₅ | Macrosporin | Antibacterial, antifungal, and cytotoxic activities as well as protein kinases' inhibitory activity | Mangrove-derived fungi <i>Phomopsis</i> sp. PSU-MA214, <i>Stemphylium</i> sp. 33 231, <i>Alternaria</i> sp. ZJ9-6B and <i>Phoma</i> sp. L28 and coral-associated fungus <i>Stemphylium lycopersici</i> and <i>Alternaria</i> sp. ZJ-2008003 | 90–94, 98, 111 and 123 |
| 109 | C ₁₆ H ₁₂ O ₈ S | Macrosporin-7-O-sulphate | Cytotoxic activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 and 94 |
| 110 | C ₂₄ H ₂₄ O ₁₁ | Macrosporin 2-O-(6'-acetyl)- α -D-glucopyranoside | Brine shrimp lethality | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 |
| 111 | C ₁₆ H ₁₆ O ₉ | Auxarthrol C | Antibacterial activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 and coral-associated fungus <i>Stemphylium lycopersici</i> | 90 and 92 |
| 112 | C ₃₂ H ₂₆ O ₁₃ | Alterporriol A | Displayed no antibacterial or cytotoxic activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 |
| 113 | C ₃₂ H ₂₆ O ₁₃ | Alterporriol B | Antibacterial activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 |
| 114 | C ₃₂ H ₂₂ O ₁₀ | Alterporriol C | Antibacterial and antiviral activities | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 and soft coral-derived <i>Alternaria</i> sp. ZJ-2008003 | 90 and 93 |
| 115 | C ₃₂ H ₃₀ O ₁₆ | Alterporriol D | Antibacterial and cytotoxic activities | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 and 94 |
| 116 | C ₃₂ H ₂₂ O ₁₀ | Alterporriol E | Antibacterial and cytotoxic activities | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 and 94 |
| 117 | C ₃₂ H ₂₆ O ₁₃ | Alterporriol N | Antibacterial and anti-inflammatory activities | Marine-derived fungus <i>Stemphylium</i> sp. FJJ006 and mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90, 95 and 97 |
| 118 | C ₃₂ H ₂₂ O ₁₀ | Alterporriol Q | Antiviral activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 and 93 |
| 119 | C ₃₂ H ₂₂ O ₁₀ | Alterporriol R | Displayed no antiviral, antibacterial or cytotoxic activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 and 93 |
| 120 | C ₃₂ H ₃₀ O ₁₃ | Alterporriol T | Displayed no antibacterial activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 |
| 121 | C ₃₂ H ₃₀ O ₁₂ | Alterporriol U | Antibacterial activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 |
| 122 | C ₃₂ H ₂₂ O ₁₀ | Alterporriol V | Antibacterial activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 |
| 123 | C ₃₂ H ₂₆ O ₁₂ | Alterporriol W | Displayed no antibacterial or cytotoxic activity | Mangrove-derived fungus <i>Stemphylium</i> sp. 33 231 | 90 |
| 124 | C ₃₂ H ₂₆ O ₁₂ | Alterporriol F | Anti-inflammatory and cytotoxic activities | Marine-derived fungus <i>Stemphylium</i> sp. FJJ006 | 95 and 96 |
| 125 | C ₃₂ H ₂₆ O ₁₃ | Alterporriol G | Antibacterial, anti-inflammatory, and cytotoxic activities as well as protein kinase inhibitory activity | Marine-derived fungus <i>Stemphylium</i> sp. FJJ006 | 95, 97 and 123 |
| 126 | C ₃₂ H ₂₆ O ₁₃ | Alterporriol Z ₁ | Anti-inflammatory activity | Marine-derived fungus <i>Stemphylium</i> sp. FJJ006 | 95 |
| 127 | C ₃₂ H ₂₆ O ₁₃ | Alterporriol Z ₂ | Anti-inflammatory activity | Marine-derived fungus <i>Stemphylium</i> sp. FJJ006 | 95 |



Table 1 (Contd.)

| Compound MF | Name | Bioactivity | Source | Ref. | |
|-------------|---|--|---|--|------------------------|
| 128 | C ₃₃ H ₂₈ O ₁₃ | Alterporriol Z ₃ | Displayed no antibacterial or cytotoxic activity | Marine-derived fungus <i>Stemphylium</i> sp. FJJ006 | 95 |
| 129 | C ₂₂ H ₂₂ O ₁₀ | Macrosporin 2-O- α -D-glucopyranoside | Displayed no cytotoxic activity | Coral associated fungus <i>Stemphylium lycopersici</i> | 92 |
| 130 | C ₃₂ H ₃₀ O ₁₂ | Alterporriol Y | Displayed no cytotoxic activity | Coral associated fungus <i>Stemphylium lycopersici</i> | 92 |
| 131 | C ₃₂ H ₂₆ O ₁₁ | Alterporriol K | Cytotoxic activity | Mangrove endophytic fungus <i>Alternaria</i> sp. ZJ9-6B | 98 |
| 132 | C ₃₂ H ₂₆ O ₁₂ | Alterporriol L | Cytotoxic activity | Mangrove endophytic fungus <i>Alternaria</i> sp. ZJ9-6B | 98 |
| 133 | C ₃₂ H ₂₆ O ₁₂ | Alterporriol M | Was not evaluated for any relevant bioactivity | Mangrove endophytic fungus <i>Alternaria</i> sp. ZJ9-6B | 98 |
| 134 | C ₃₂ H ₃₀ O ₁₄ | Alterporriol O | Displayed no antibacterial, antiviral, or cytotoxic activity | Soft coral derived <i>Alternaria</i> sp. ZJ-2008003 | 93 |
| 135 | C ₃₂ H ₂₆ O ₁₂ | Alterporriol P | Cytotoxic activity | Soft coral derived <i>Alternaria</i> sp. ZJ-2008003 | 93 |
| 136 | C ₁₆ H ₂₀ O ₆ | Tetrahydroaltersolanol C | Antiviral activity | Mangrove-derived fungus <i>Phomopsis</i> sp. PSU-MA214 and soft coral-derived fungus <i>Alternaria</i> sp. ZJ-2008003 | 93 and 111 |
| 137 | C ₁₆ H ₂₀ O ₆ | Tetrahydroaltersolanol D | Displayed no antibacterial, antiviral, or cytotoxic activity | Soft coral derived <i>Alternaria</i> sp. ZJ-2008003 | 93 |
| 138 | C ₁₆ H ₂₀ O ₆ | Tetrahydroaltersolanol E | Displayed no antibacterial, antiviral, or cytotoxic activity | Soft coral derived <i>Alternaria</i> sp. ZJ-2008003 | 93 |
| 139 | C ₁₈ H ₂₂ O ₇ | Tetrahydroaltersolanol F | Displayed no antibacterial, antiviral, or cytotoxic activity | Soft coral derived <i>Alternaria</i> sp. ZJ-2008003 | 93 |
| 140 | C ₂₅ H ₂₈ O ₁₀ | Anthrinenone A | Inhibitory activity on protein tyrosine phosphatases and stimulatory effect on intracellular calcium levels | Deep-sea derived fungus <i>Alternaria tenuissima</i> DFFSCS013 | 99 |
| 141 | C ₁₆ H ₁₂ O ₆ | 6-O-methyl-alaternin | Inhibitory activity on protein tyrosine phosphatases | Deep-sea derived fungus <i>Alternaria tenuissima</i> DFFSCS013 | 99 |
| 142 | C ₁₆ H ₁₆ O ₅ | (3R)-1-deoxyaustrocortilutein | Displayed no stimulation of intracellular calcium level | Deep-sea derived fungus <i>Alternaria tenuissima</i> DFFSCS013 | 99 |
| 143 | C ₁₅ H ₁₆ O ₅ | Harzianumnone A | Displayed no anti-acetylcholinesterase or DNA Topo I inhibitory activities | Coral-derived fungus <i>T. harzianum</i> XS-20090075 | 100 |
| 144 | C ₁₅ H ₁₆ O ₅ | Harzianumnone B | Displayed no anti-acetylcholinesterase or DNA Topo I inhibitory activities | Coral-derived fungus <i>T. harzianum</i> XS-20090075 | 100 |
| 145 | C ₁₅ H ₁₀ O ₄ | Phomarin | Anti-acetylcholinesterase activity | Coral-derived fungus <i>T. harzianum</i> XS-20090075 | 100 |
| 146 | C ₁₅ H ₁₀ O ₅ | ω -hydroxydigitoemodin | Anti-acetylcholinesterase activity | Coral-derived fungus <i>T. harzianum</i> XS-20090075 | 100 |
| 147 | C ₁₅ H ₁₀ O ₃ | Pachybasin | Anti-acetylcholinesterase and cytotoxic activities | Marine-derived fungus <i>T. aureoviride</i> PSU-F95 and mangrove endophytic fungi <i>Halorosellinia</i> sp. (no. 1403) and <i>Guignardia</i> sp. (no. 4382), and sea urchin-derived fungus <i>Monodictys</i> sp. | 40, 41, 54, 55 and 100 |
| 148 | C ₁₇ H ₁₄ O ₆ | (+)-2'S-isorhodoptilometrin | Anti-acetylcholinesterase, antibacterial, and cytotoxic activities, as well as DNA Topo I inhibitory activity | Coral-derived fungus <i>T. harzianum</i> XS-20090075, marine lichen-derived fungus <i>Gliocladium</i> sp. T31, and marine-derived fungus <i>T. aureoviride</i> PSU-F95 | 54, 56 and 100 |
| 149 | C ₁₅ H ₁₀ O ₄ | ω -hydroxypachybasin | Antibacterial, and cytotoxic activities, as well as DNA Topo I inhibitory activity | Marine-derived fungus <i>T. aureoviride</i> PSU-F95 and coral-derived fungus <i>T. harzianum</i> XS-20090075 | 54 and 100 |
| 150 | C ₁₅ H ₁₄ O ₅ | Coniothranthraquinone 1 | Antibacterial activity | Marine-derived fungus <i>T. aureoviride</i> PSU-F95 | 54 |
| 151 | C ₁₅ H ₁₄ O ₆ | Trichodermaquinone | Antibacterial activity | Marine-derived fungus <i>T. aureoviride</i> PSU-F95 | 54 |
| 152 | C ₁₅ H ₁₀ O ₄ | 2-Methyl-quinizarin | Was not evaluated for any relevant bioactivity | Marine-derived fungus <i>T. aureoviride</i> PSU-F95 | 54 |



Table 1 (Contd.)

| Compound MF | Name | Bioactivity | Source | Ref. | |
|-------------|---|---|--|--|-------------|
| 153 | C ₁₅ H ₁₀ O ₄ | 1-Hydroxy-3-methoxyanthraquinone | Was not evaluated for any relevant bioactivity | Marine-derived fungus <i>T. aureoviride</i> PSU-F95 | 54 |
| 154 | C ₁₅ H ₁₆ O ₅ | Coniothyronone A | Antibacterial and antiangiogenetic activities | Marine-derived fungus <i>Trichoderma</i> sp. and saline-alkali plant endophytic fungus <i>Eu. rubrum</i> | 60 and 103 |
| 155 | C ₁₅ H ₁₄ O ₆ | Lentisone | Antibacterial and antiangiogenetic activities | Marine-derived fungus <i>Trichoderma</i> sp | 60 |
| 156 | C ₁₅ H ₁₂ O ₅ | 9-Dehydroxyeurotinone | Antibacterial and cytotoxic activities | Marine-derived endophytic fungus <i>Eu. rubrum</i> | 58 |
| 157 | C ₁₆ H ₁₄ O ₅ | 2-O-Methyl-9-dehydroxyeurotinone | Antioxidant activity | Marine-derived endophytic fungus <i>Eu. rubrum</i> and marine mangrove-derived endophytic fungus <i>Eu. rubrum</i> | 58 and 62 |
| 158 | C ₂₁ H ₂₂ O ₉ | 2-O-Methyl-4-O-(α -D-ribofuranosyl)-9-dehydroxyeurotinone | Antioxidant activity | Marine mangrove-derived endophytic fungus <i>Eu. rubrum</i> | 62 |
| 159 | C ₂₁ H ₂₀ O ₉ | 3-O-(α -D-ribofuranosyl)-questin | Antibacterial and antioxidant activities | Marine mangrove-derived endophytic fungus <i>Eu. rubrum</i> and marine algae-derived endophytic fungus <i>Eu. cristatum</i> EN-220 | 62 and 101 |
| 160 | C ₃₃ H ₃₂ O ₁₀ | Eurorubrin | Antibacterial and antioxidant activities as well as brine shrimp lethality | Marine mangrove-derived endophytic fungus <i>Eu. rubrum</i> and marine algae-derived endophytic fungus <i>Eu. cristatum</i> EN-220 | 62 and 101 |
| 161 | C ₂₁ H ₂₀ O ₁₀ | 3-O-(α -D-ribofuranosyl)questinol | Displayed no antibacterial activity or brine shrimp lethality | Marine algae-derived endophytic fungus <i>Eu. cristatum</i> EN-220 | 101 |
| 162 | C ₂₁ H ₂₄ O ₉ | Asperflavin ribofuranoside | Antibacterial and antioxidant activities | Marine algae-derived endophytic fungus <i>Eu. cristatum</i> EN-220 and marine-derived algicolous fungus <i>Microsporium</i> sp | 101 and 102 |
| 163 | C ₁₅ H ₁₄ O ₅ | Rubrumol | Relaxation activity on Topo I enzyme | Saline-alkali plant endophytic fungus <i>Eu. rubrum</i> | 103 |
| 164 | C ₁₆ H ₁₆ O ₆ | Nigrosporin A | Antibacterial, cytotoxic, and phytotoxic activities | Sea fan-derived fungus <i>Fusarium</i> sp. PSU-F14 | 39 and 44 |
| 165 | C ₁₆ H ₂₀ O ₇ | Fusaranthraquinone | Displayed no antibacterial activity | Sea fan-derived fungus <i>Fusarium</i> sp. PSU-F14 | 39 |
| 166 | C ₁₆ H ₁₈ O ₆ | Fusaquinon A | Cytotoxic activity | Marine-derived fungus <i>Fusarium</i> sp. ZH-210 | 104 and 105 |
| 167 | C ₁₆ H ₂₀ O ₈ | Fusaquinon B | Cytotoxic activity | Marine-derived fungus <i>Fusarium</i> sp. ZH-210 | 104 |
| 168 | C ₁₆ H ₂₀ O ₇ | Fusaquinon C | Cytotoxic activity | Marine-derived fungus <i>Fusarium</i> sp. ZH-210 | 104 |
| 169 | C ₂₁ H ₂₀ O ₅ | 6,8-Dimethoxy-1-methyl-2-(3-oxobutyl)anthracene-9,10-dione | Cytotoxic activity | Mangrove endophytic fungus <i>Fusarium</i> sp. ZZF60 | 106 |
| 170 | C ₁₇ H ₁₂ O ₇ | 5-Acetyl-2-methoxy-1,4,6-trihydroxy-anthraquinone | Was not evaluated for any relevant bioactivity | Marine endophytic fungus <i>Fusarium</i> sp. b77 | 124 |
| 171 | C ₃₃ H ₂₈ O ₁₂ | Engyodontochone A | Antibacterial, antifungal, and cytotoxic activities | Marine-derived fungus <i>Engyodontium album</i> strain LF069 | 23 |
| 172 | C ₃₃ H ₂₈ O ₁₂ | JBIR-99 | Antibacterial, antifungal, and cytotoxic activities | Marine-derived fungus <i>Engyodontium album</i> strain LF069 | 23 |
| 173 | C ₃₃ H ₂₈ O ₁₂ | Engyodontochone B | Antibacterial, antifungal, and cytotoxic activities | Marine-derived fungus <i>Engyodontium album</i> strain LF069 | 23 |
| 174 | C ₃₃ H ₂₈ O ₁₂ | Engyodontochone C | Antibacterial and cytotoxic activities | Marine-derived fungus <i>Engyodontium album</i> strain LF069 | 23 |
| 175 | C ₃₃ H ₃₀ O ₁₃ | Engyodontochone F | Antibacterial and antifungal activities | Marine-derived fungus <i>Engyodontium album</i> strain LF069 | 23 |
| 176 | C ₃₃ H ₃₀ O ₁₃ | Engyodontochone E | Antibacterial activity | Marine-derived fungus <i>Engyodontium album</i> strain LF069 | 23 |
| 177 | C ₃₃ H ₂₈ O ₁₂ | Engyodontochone D | Was not evaluated for any relevant bioactivity | Marine-derived fungus <i>Engyodontium album</i> strain LF069 | 23 |
| 178 | C ₁₆ H ₁₆ O ₇ | 4-Dehydroxyaltersolanol A | Antibacterial and anticoagulant activities | Marine-derived fungus <i>Sporendonema casei</i> HDN16-802 | 107 |
| 179 | C ₁₆ H ₁₈ O ₈ | Auxarthrol D | Antibacterial, anticoagulant, and cytotoxic activities | Marine-derived fungus <i>Sporendonema casei</i> HDN16-802 | 107 |



Table 1 (Contd.)

| Compound MF | Name | Bioactivity | Source | Ref. | |
|-------------|--|---|---|---|-----------|
| 180 | C ₁₆ H ₂₀ O ₉ | Auxarthrol E | Anticoagulant activity | Marine-derived fungus <i>Sporendonema casei</i> HDN16-802 | 107 |
| 181 | C ₁₆ H ₂₀ O ₈ | Auxarthrol F | Antibacterial, anticoagulant, and cytotoxic activities | Marine-derived fungus <i>Sporendonema casei</i> HDN16-802 | 107 |
| 182 | C ₁₆ H ₁₇ ClO ₈ | Auxarthrol G | Antibacterial, anticoagulant, and antifungal activities | Marine-derived fungus <i>Sporendonema casei</i> HDN16-802 | 107 |
| 183 | C ₁₆ H ₁₈ O ₈ | Auxarthrol H | Anticoagulant activity | Marine-derived fungus <i>Sporendonema casei</i> HDN16-802 | 107 |
| 184 | C ₁₇ H ₁₄ O ₄ | 1,3-Dimethoxy-6-methyl-anthracene-9,10-dione | Cytotoxic activity | Mangrove endophytic fungi <i>Halorosellinia</i> sp. No. 1403 and <i>Guignardia</i> sp. No. 4382 | 40 |
| 185 | C ₁₅ H ₁₀ O ₄ | Demethoxyaustrocortirubin | Cytotoxic activity | Mangrove endophytic fungi <i>Halorosellinia</i> sp.No. 1403 and <i>Guignardia</i> sp. No. 4382 | 40 and 41 |
| 186 | C ₁₄ H ₈ O ₄ | Dantron | Cytotoxic activity | Mangrove endophytic fungi <i>Halorosellinia</i> sp.No. 1403 and <i>Guignardia</i> sp. No. 4382 | 40 |
| 187 | C ₁₆ H ₁₂ O ₅ | 1,3-Dihydroxy-6-methoxy-8-methyl-anthracene-9,10-dione | Cytotoxic activity | Mangrove endophytic fungi <i>Halorosellinia</i> sp.No. 1403 and <i>Guignardia</i> sp. No. 4382 | 40 |
| 188 | C ₁₇ H ₁₄ O ₅ | 1-Hydroxy-2,4-dimethoxy-7-methyl-anthracene-9,10-dione | Cytotoxic activity | Mangrove endophytic fungi <i>Halorosellinia</i> sp.No. 1403 and <i>Guignardia</i> sp. No. 4382 | 40 |
| 189 | C ₁₆ H ₁₂ O ₄ | 8-Hydroxy-1-methoxy-3-methyl-9,10-anthraquinone | Cytotoxic activity | Mangrove endophytic fungi <i>Halorosellinia</i> sp.No. 1403 and <i>Guignardia</i> sp. No. 4382 | 40 |
| 190 | C ₁₇ H ₁₄ O ₆ | 1,7-Dihydroxy-2,4-dimethoxy-6-methyl-anthracene-9,10-dione | Cytotoxic activity | Mangrove endophytic fungi <i>Halorosellinia</i> sp.No. 1403 and <i>Guignardia</i> sp. No. 4382 | 40 |
| 191 | C ₁₄ H ₈ O ₅ | 1,3,8-Trihydroxyanthraquinone | Cytotoxic activity | Mangrove endophytic fungi <i>Halorosellinia</i> sp.No. 1403 and <i>Guignardia</i> sp. No. 4382 | 40 |
| 192 | C ₁₆ H ₁₂ O ₆ | 1,4,7-Trihydroxy-2-methoxy-6-methyl-9,10-anthraquinone | Displayed no cytotoxic activity | Mangrove endophytic fungi <i>Halorosellinia</i> sp.No. 1403 and <i>Guignardia</i> sp. No. 4382 | 40 |
| 193 | C ₁₆ H ₁₆ O ₈ | SZ-685C | Cytotoxic activity | Mangrove endophytic fungus <i>Halorosellinia</i> sp. No. 1403 | 108–110 |
| 194 | C ₁₈ H ₂₀ O ₆ | Phomopsantraquinone | Antibacterial and cytotoxic activities | Mangrove-derived fungus <i>Phomopsis</i> sp. PSU-MA214 | 111 |
| 195 | C ₁₆ H ₁₂ O ₄ | 1-Hydroxy-3-methoxy-6-methyl-anthraquinone | Displayed no antibacterial or cytotoxic activity | Mangrove-derived fungus <i>Phomopsis</i> sp. PSU-MA214 | 111 |
| 196 | C ₁₆ H ₁₂ O ₇ | Tetrahydroxyanthraquinone | Protein kinases' inhibitory activity | Sponge-associated fungus <i>Microsphaeropsis</i> sp | 112 |
| 197 | C ₁₇ H ₁₄ O ₇ | Methoxyl-tetrahydroxyanthraquinone | Protein kinases' inhibitory activity | Sponge-associated fungus <i>Microsphaeropsis</i> sp | 112 |
| 198 | C ₁₇ H ₁₄ O ₈ | 1,2,3,6,8-Pentahydroxy-7-[(1R)-1-methoxyethyl]-9,10-anthraquinone | Protein kinases' inhibitory activity | Sponge-associated fungus <i>Microsphaeropsis</i> sp | 112 |
| 199 | C ₁₅ H ₁₀ O ₆ | Lunatin | Antibacterial activity | Sponge-derived fungus <i>Curvularia lunata</i> | 113 |
| 200 | C ₃₀ H ₂₂ O ₁₂ | Cytoskyrin A | Antibacterial activity | Sponge-derived fungus <i>Curvularia lunata</i> | 113 |
| 201 | C ₁₄ H ₈ O ₆ | Rheoemodin | Displayed no significant anti-obesity activity | Marine sponge-associated fungus <i>Talaromyces stipitatus</i> KUFA 0207 | 82 |
| 202 | C ₃₀ H ₁₈ O ₁₀ | 2, 2'-Bis-(7-methyl-1,4,5-trihydroxy-anthracene-9,10-dione) | Was not evaluated for any relevant activity | Marine sponge-associated fungus <i>Talaromyces stipitatus</i> KUFA 0207 | 82 |
| 203 | C ₁₇ H ₁₄ O ₅ | 7-Methoxymacrosporin | Antifungal activity | Mangrove-derived fungus <i>Phoma</i> sp. L28 | 91 |
| 204 | C ₂₁ H ₂₀ O ₅ | 7-(γ,γ)-Dimethyl-allyloxy-macrosporin | Antifungal activity | Mangrove-derived fungus <i>Phoma</i> sp. L28 | 91 |
| 205 | C ₁₆ H ₁₂ O ₅ | Monodictyquinone A | Antibacterial and antifungal activities | Sea urchin-derived fungus <i>Monodictys</i> sp | 55 |
| 206 | C ₁₆ H ₁₂ O ₆ | 1,3,6-Trihydroxy-7-(1-hydroxyethyl)anthracene-9,10-dione | Inhibitory activity against α-glycosidase | Mangrove-derived fungus <i>Cladosporium</i> sp. HNWSW-1 | 114 |



Table 1 (Contd.)

| Compound MF | Name | Bioactivity | Source | Ref. | |
|-------------|--|------------------------------|---|--|-------------|
| 207 | C ₁₇ H ₁₂ O ₇ | Phaseolorin I | Displayed no cytotoxic activity | Deep-sea sediment-derived fungus <i>Diaporthe phaseolorum</i> FS431 | 115 |
| 208 | C ₂₂ H ₂₂ O ₇ | 6,8-O,O'-Dimethyl-averufanin | Antifungal and phytotoxic activities, as well as brine shrimp lethality | Mangrove endophytic fungus ZSUH-36 | 116 and 117 |

5 tested drug-likeness rules (7, 48, 7, 4, 10, 16, 10, 9, 2, and 20 anthraquinones from *Nigrospora*, *Aspergillus*, *Penicillium*, *Stemphylium*, *Alternaria*, *Trichoderma*, *Eurotium*, *Fusarium*, *Sporendonema casei*, and the other genera, respectively). Noteworthy, all anthraquinones identified from *Trichoderma* species fulfilled the 5 rules. On the other hand, all *Engyodontium album* derived compounds violated the 5 tested rules (Fig. 15, 16, and S† Table 1).

Topological polar surface area (TPSA), another measure, is the sum of the surfaces of all the polar atoms present in a molecule. TPSA has a substantial effect on the potential of a compound to penetrate through the cell membranes and blood–brain barrier. Veber highlighted those compounds with $TPSA \leq 140 \text{ \AA}^2$ tend to be well absorbed and able to reach their molecular target within the body cells. Egan stated that molecules with TPSA less than 132 \AA^2 and log-P between -1 and 6 could be considered leads with high drug-likeness potential and good orally bioavailability. Muegge utilized a pharmacophore point filter based on very simple structural rules to differentiate between drug-like and nondrug-like molecules, among them TPSA not greater than 150 \AA^2 as well as rotatable bonds (RB), not more than 15. All anthraquinones from *Fusarium*, *Trichoderma*, *Nigrospora* (except compound 1), *Aspergillus* (except compounds 11, 12, 20, 24, 25, 39, and 61), *Penicillium* (except compounds 81, 82, 86, and 89–96), *Stemphylium* (except compounds 110–130), *Alternaria* (except compounds 114, 131–135, and 140), *Eurotium* (except compounds 20, 160, and 161), *Sporendonema casei* (except compound 180), and the other genera (except compounds 200 and 202) had TPSA less than 150 \AA^2 . On the other hand, all *Engyodontium album* derived compounds had TPSA greater than 150 \AA^2 . All anthraquinones had RB less than 15 (Fig. 15 and ESI Table S1†).

Oral bioavailability, bioavailability score (BS), is another descriptor that indicates the possibility of a compound to be bioavailable with more than 10% in the absorption assays. Molecules obeying the Lipinski rule with BS of 0.55 are considered orally bioavailable. Interestingly, 166 anthraquinones showed a BS of 0.55. In alignment with other parameters, all *Fusarium* and *Trichoderma* derived anthraquinones showed a BS of 0.55 and all *Engyodontium album* derived compounds had a BS of 0.11. Compounds 3, 6, and 9, are of special interest as they showed a good BS of 0.56. Some other compounds, among them 10, 87, 97, and 109, showed good BS (0.56); however, violated one or more drug-likeness rules (Fig. 15 and ESI Table S1†).

Oral bioavailability relies as well on the degree of the molecular flexibility of the molecule. Candidates with an extreme degree of flexibility do not typically display acceptable bioavailability as they tend to be less planar and with very complex 3D shapes. The sp^3 carbons fraction (Fraction Csp^3) and the number of RB are two crucial measures for molecular flexibility. Csp^3 is the ratio of the sp^3 carbon atoms to the total carbons present in a given compound. It assigns the degree of carbon saturation, characterizes the space complexity, and correlates to the solubility of the compound. A Csp^3 score between 0.25 and 1 is considered optimum for drug-likeness. One hundred anthraquinones, distributed in all marine fungi species, displayed a Csp^3 score ranging between 0.28 and 0.6. The water solubility, expressed as log S, is another essential measure for drug bioavailability. Compounds with poor water solubility have poor absorption and oral bioavailability, as well as low formulation potential. Anthraquinones revealed different solubility orders as *Sporendonema casei* derived compounds were the most soluble (mean value of -1.46), followed by *Nigrospora* sp (mean value of -2.34), while *Engyodontium album* derived anthraquinones, as expected, were the most poorly soluble (mean value of -5.44) (Fig. 15 and ESI Table S1†).

Gastrointestinal (GI) absorption, blood–brain barrier (BBB) permeation, P-glycoprotein (P-gp) substrate and cytochrome P450 members inhibition potentials were also surveyed to draw insight about the pharmacokinetic behavior of the reviewed anthraquinones. Twenty anthraquinones (47, 48, 49, 51, 52, 57, 83, 147, 152, 153, 157, 169, 184, 185, 186, 188, 189, 195, 203, and 204) showed high GI absorption, passively crossed BBB and did not show any potential for P-gp substrate (ESI Table S2†). Surprisingly, compound 169 obeyed all the surveyed parameters (5 drug-likeness rules, log P, Csp^3 , RB, TPSA, log S, GI, BBB, Pgp) and the other 19 anthraquinones as well except for fraction Csp^3 . Noteworthy, all but one of the 20 anthraquinones have two benzenoid aromatic rings and two C=O groups. Also, several anthraquinones showed potential inhibition for some CYP 450 isoforms which necessitates awareness when co-administered with possible substrates of these enzymes (ESI Table S2†).

To sum up, marine fungi are a promising source of biologically active anthraquinones that obeyed all the criteria of several drug-likeness rules with promising pharmacokinetic behavior which promotes their utilization as well as further research to isolate their individual components and determine their pharmacological effects.






Fig. 17 Distribution and total anthraquinones and their derivatives isolated from different species of marine-derived fungi.




Fig. 18 Total biological activities of various anthraquinones and their derivatives isolated from different species of marine-derived fungi.

Conclusions and future prospective

The marine phoma is representing the most, the greatest and most diverse ecological structure on the planet. Over seven decades, marine natural products (MNPs) have owned credits and been privileged as a robust and sustainable supplier for pharmacologically active compounds that meet a huge interest in pharmaceutical and economical applications. Marine-derived fungi are valuable sources of structurally diverse MNPs due to their various habitats that range from the warm to the colder areas, and even at extreme temperatures and pressure like in hydrothermal outlets. One of the fascinating classes of fungal derived natural products is the anthraquinones. Herein, we presented a comprehensive literature review centered on marine-derived anthraquinones as a unique group of fungal polyketides over the period 2000–2020 from twenty

marine fungal genera. A list of 208 anthraquinones have been reported from different marine fungi, featuring a myriad of structural and biological diversities. Investigating such extensive chemo-biological data has implied two remarkable points. First, it was clear that the marine fungi of the three genera *Aspergillus* sp., *Stemphylium* sp., and *Penicillium* sp., are the most creative fungal genera in terms of producing of anthraquinones. Secondly, the most common reported bioactivity was cytotoxicity, where a notable number of seventy-two compounds have been evaluated for their cytotoxic activity against planes of carcinoma cell lines, whilst the anthraquinones with antibacterial activity were the second on the list with sixty-nine compounds demonstrated bioactivity against a wide range of microorganisms. Meanwhile, an enormous spectrum of further biomedical potentialities exhibited by these compounds as (antioxidant, antiviral, antifungal, immunomodulatory, anti-



inflammatory,etc.) have been documented. Such a massive connection between chemical spaces and bioactivities highlights the huge capacity of marine-derived fungi as an attractive biological source that is worth further exploitations with distinguished anticipations for the global pharmaceuticals industries. Additionally, recent advances in the level of sampling techniques, fermentation, synthetic biology, genetic engineering, genome mining, and total chemical synthesis, all are crucial to the success of fungal MNPs as future drug leads. Furthermore, all reported anthraquinones were extensively investigated for their *in silico* Drug-likeness and pharmacokinetics properties using SWISSADME online platform, which intriguingly highlighted a list of 20 anthraquinone containing compounds (ESI†) that could be considered as potential drug leads scaffolds (Fig. 17 and 18).

Author contributions

Conceptualization: Amr El-Demerdash. Validation: Amr El-Demerdash. Formal analysis: Mohamed Sebak, Fatma Molham, Claudio Greco Mohamed A. Tammam, Mansour Sobeh and Amr El-Demerdash. Investigation: Mohamed Sebak, Fatma Molham, Claudio Greco Mohamed A. Tammam, Mansour Sobeh and Amr El-Demerdash. Resources: Mohamed Sebak, Fatma Molham, Claudio Greco Mohamed A. Tammam, Mansour Sobeh and Amr El-Demerdash. Data curation: Mohamed Sebak, Fatma Molham, Claudio Greco Mohamed A. Tammam, Mansour Sobeh and Amr El-Demerdash. Writing original draft: Mohamed Sebak, Fatma Molham, Claudio Greco Mohamed A. Tammam, Mansour Sobeh and Amr El-Demerdash. Writing-review & editing: Mohamed Sebak, Fatma Molham, Claudio Greco Mohamed A. Tammam, Mansour Sobeh and Amr El-Demerdash.

Conflicts of interest

The authors declare that they have no known competing commercial interests or personal relationships that could have appeared to influence the work reported in this paper.

Funding

Amr El-Demerdash is immensely grateful to the John Innes Centre, Norwich Research Park, United Kingdom for the post-doctoral fellowship. Claudio Greco was supported by the BBSRC (BB/V005723/1).

List of abbreviations

| | |
|-------|-----------------------|
| A. | <i>Aspergillus</i> |
| ACP | acyl carrier protein |
| AT | acyl transferase |
| B. | <i>Bacillus</i> |
| BBB | blood–brain barrier |
| BS | bioavailability score |
| C | <i>Candida</i> |
| Cox-2 | cyclooxygenase-2 |

| | |
|-------------------|--|
| Csp ³ | sp ³ carbons |
| DPPH | 1,1-diphenyl-2-picrylhydrazyl |
| E. | <i>Escherichia</i> |
| ED ₅₀ | median effective dose (the dose which produces a specified effect in 50% of the population in a study) |
| Eu. | <i>Eurotium</i> |
| F. | <i>Fusarium</i> |
| FCsp ³ | fraction of sp ³ carbons |
| HCV | Hepatitis C virus |
| GI | Gastrointestinal |
| KS | ketosynthase |
| IC ₅₀ | inhibitory concentration that causes a 50% reduction in cell viability |
| IL | interleukin |
| LD ₅₀ | lethal dose 50 (the dose which produces death in 50% of the population in a study) |
| Log P | lipophilicity |
| Log S | solubility |
| M. | <i>Mycobacterium</i> |
| MdpF | metallo-hydrolase protein |
| MIC | minimum inhibitory concentration |
| MNP | marine natural product |
| MRSA | methicillin-resistant <i>Staphylococcus aureus</i> |
| Mwt | molecular weight |
| nrPKS | non-reducing polyketide synthase |
| P. | <i>Penicillium</i> |
| P-gp | P-glycoprotein |
| PT | product template |
| RB | rotatable bond |
| S. | <i>Staphylococcus</i> |
| SAT | starter unit-ACP transacylase |
| Str. | <i>Streptococcus</i> |
| T. | <i>Trichoderma</i> |
| Topo | topoisomerase |
| TPSA | topological polar surface area |
| V. | <i>Vibrio</i> |

Acknowledgements

Amr El-Demerdash is immensely thankful to his home university, Mansoura University, Egypt for the unlimited support, inside and outside.

References

- D. J. Newman and G. M. Cragg, *J. Nat. Prod.*, 2016, **79**, 629–661.
- A. G. Atanasov, B. Waltenberger, E.-M. Pferschy-Wenzig, T. Linder, C. Wawrosch, P. Uhrin, V. Temml, L. Wang, S. Schwaiger and E. H. Heiss, *Biotechnol. Adv.*, 2015, **33**, 1582–1614.
- M. A. Ghareeb, M. A. Tammam, A. El-Demerdash and A. G. Atanasov, *Curr. Res. Biotechnol.*, 2020, **2**, 88–102.
- A. El-Demerdash, D. Kumla and A. Kijjoa, *Mar. Drugs*, 2020, **18**, 1–32.
- M. Sebak, A. E. Saafan, S. AbdelGhani, W. Bakeer, A. O. El-Gendy, L. C. Espriu, K. Duncan and R. Edrada-Ebel, *PLoS One*, 2019, **14**, 1–29.



- 6 N. Osama, W. Bakeer, M. Raslan, H. A. Soliman, U. R. Abdelmohsen and M. Sebak, *R. Soc. Open Sci.*, 2022, **9**, 211509.
- 7 W. Sun, W. Wu, X. Liu, D. A. Zaleta-Pinet and B. R. Clark, *Mar. Drugs*, 2019, **17**, 339.
- 8 A. R. Carroll, B. R. Copp, R. A. Davis, R. A. Keyzers and M. R. Prinsep, *Nat. Prod. Rep.*, 2019, **36**, 122–173.
- 9 P. Shinde, P. Banerjee and A. Mandhare, *Expert Opin. Ther. Pat.*, 2019, **29**, 283–309.
- 10 L. Macintyre, T. Zhang, C. Viegelmann, I. J. Martinez, C. Cheng, C. Dowdells, U. R. R. Abdelmohsen, C. Gernert, U. Hentschel and R. A. Edrada-Ebel, *Mar. Drugs*, 2014, **12**, 3416–3448.
- 11 L. Van Andel, H. Rosing, J. H. M. Schellens and J. H. Beijnen, *Mar. Drugs*, 2018, **16**, 246.
- 12 G. M. Cragg and D. J. Newman, *Biochim. Biophys. Acta - Gen. Subj.*, 2013, **1830**, 3670–3695.
- 13 J. W. Blunt, B. R. Copp, R. A. Keyzers, M. H. G. Munro and M. R. Prinsep, *Nat. Prod. Rep.*, 2015, **32**, 116–211.
- 14 R. Montaser and H. Luesch, *Future Med. Chem.*, 2011, **3**, 1475–1489.
- 15 S. R. Damare, 2006.
- 16 M. Fouillaud, M. Venkatachalam, E. Girard-Valenciennes, Y. Caro and L. Dufossé, *Mar. Drugs*, 2016, **14**(4), 64.
- 17 S. K. Deshmukh, V. Prakash and N. Ranjan, *Front. Microbiol.*, 2018, **8**, 1–24.
- 18 H. J. Shin, *Mar. Drugs*, 2020, **18**, 230.
- 19 C. Montagne, Durieu Maisonneuve, MC, *Explor. Sci. l'Algerie pendant les annees 1840, 1841, 1842....*, *Sci. Phys. Bot. Cryptogam.*, 1846, **1**, 1–197.
- 20 A. Amend, G. Burgaud, M. Cunliffe, V. P. Edgcomb, C. L. Ettinger, M. H. Gutiérrez, J. Heitman, E. F. Y. Hom, G. Ianiri, A. C. Jones, M. Kagami, K. T. Picard, C. A. Quandt, S. Raghukumar, M. Riquelme, J. Stajich, J. Vargas-Muñiz, A. K. Walker, O. Yarden and A. S. Gladfelter, *MBio*, 2019, **10**(2), DOI: [10.1128/mBio.01189-18](https://doi.org/10.1128/mBio.01189-18).
- 21 M. S. Butler, A. A. B. Robertson and M. A. Cooper, *Nat. Prod. Rep.*, 2014, **31**, 1612–1661.
- 22 B. Wu, G. Chen, Z. Liu and Y. Pei, *Rec. Nat. Prod.*, 2015, **9**, 271.
- 23 B. Wu, J. Wiese, A. Wenzel-Storjohann, S. Malien, R. Schmaljohann and J. F. Imhoff, *Chem. - A Eur. J.*, 2016, **22**, 7452–7462.
- 24 J. R. Hanson, *Natural products: the secondary metabolites*, Royal Society of Chemistry, 2003, vol. 17.
- 25 R. Ebel, in *Comprehensive Natural Products II: Chemistry and Biology*, Elsevier Ltd, 2010, pp. 223–262.
- 26 N. N. Gessler, A. S. Egorova and T. A. Belozerskaya, *Appl. Biochem. Microbiol.*, 2013, **49**, 85–99.
- 27 C. Greco, K. de Mattos-Shiple, A. M. Bailey, N. P. Mulholland, J. L. Vincent, C. L. Willis, R. J. Cox and T. J. Simpson, *Chem. Sci.*, 2019, **10**, 2930–2939.
- 28 M. Masi and A. Evidente, *Toxins*, 2020, **12**, 714.
- 29 G. Greco, E. Turrini, E. Catanzaro and C. Fimognari, *Mar. Drugs*, 2021, **19**, 272.
- 30 A. El-Demerdash, *J. Fungi*, 2018, **4**, 130.
- 31 A. El-Demerdash, G. Genta-Jouve, M. Bärenstrauch, C. Kunz, E. Baudouin and S. Prado, *Phytochemistry*, 2019, **166**, 112056.
- 32 A. J. Birch, J. Baldas, J. R. Hlubucek, T. J. Simpson and P. W. Westerman, *J. Chem. Soc. Perkin Trans.*, 1976, **1**, 898–904.
- 33 A. J. Birch and F. W. Donovan, *Stud. Relat. to biosynthesis. I. Some possible routes ro Deriv. orcinol phloroglucinol*, *Aust. J. Chem.*, 1953, **6**, 360–368.
- 34 Y.-M. Chiang, B. R. Oakley, N. P. Keller and C. C. C. Wang, *Appl. Microbiol. Biotechnol.*, 2010, **86**, 1719–1736.
- 35 T. J. Simpson, *ChemBioChem*, 2012, **13**, 1680–1688.
- 36 S. Griffiths, C. H. Mesarich, B. Saccomanno, A. Vaisberg, P. J. G. M. De Wit, R. Cox and J. Collemare, *Proc. Natl. Acad. Sci.*, 2016, **113**, 6851–6856.
- 37 W. F. Xu, X. M. Hou, K. L. Yang, F. Cao, R. Y. Yang, C. Y. Wang and C. L. Shao, *Mar. Drugs*, 2016, **14**, 51.
- 38 K. L. Yang, M. Y. Wei, C. L. Shao, X. M. Fu, Z. Y. Guo, R. F. Xu, C. J. Zheng, Z. G. She, Y. C. Lin and C. Y. Wang, *J. Nat. Prod.*, 2012, **75**, 935–941.
- 39 K. Trisuwan, N. Khamthong, V. Rukachaisirikul, S. Phongpaichit, S. Preedanon and J. Sakayaroj, *J. Nat. Prod.*, 2010, **73**, 1507–1511.
- 40 J. Y. Zhang, L. Y. Tao, Y. J. Liang, L. M. Chen, Y. J. Mi, L. S. Zheng, F. Wang, Z. G. She, Y. C. Lin, K. K. W. To and L. W. Fu, *Mar. Drugs*, 2010, **8**, 1469–1481.
- 41 X. K. Xia, H. R. Huang, Z. G. She, C. L. Shao, F. Liu, X. L. Cai, L. L. P. Vrijmoed and Y. C. Lin, *Magn. Reson. Chem.*, 2007, **45**, 1006–1009.
- 42 J. Xu, T. Nakazawa, K. Ukai, H. Kobayashi, R. E. P. Mangindaan, D. S. Wewengkang, H. Rotinsulu and M. Namikoshi, *J. Antibiot.*, 2008, **61**, 415–419.
- 43 C. Wang, J. Wang, Y. Huang, H. Chen, Y. Li, L. Zhong, Y. Chen, S. Chen, J. Wang, J. Kang, Y. Peng, B. Yang, Y. Lin, Z. She and X. Lai, *Molecules*, 2013, **18**, 1728–1740.
- 44 M. Tanaka, T. Fukushima, Y. Tsujino and T. Fujimori, *Biosci. Biotechnol. Biochem.*, 1997, **61**, 1848–1852.
- 45 X. Xia, Q. Li, J. Li, C. Shao, J. Zhang, Y. Zhang, X. Liu, Y. Lin, C. Liu and Z. She, *Planta Med.*, 2011, **77**, 1735–1738.
- 46 U. Sommart, V. Rukachaisirikul, Y. Sukpondma, S. Phongpaichit, J. Sakayaroj and K. Kirtikara, *Chem. Pharm. Bull.*, 2008, **56**, 1687–1690.
- 47 L. Du, T. Zhu, H. Liu, Y. Fang, W. Zhu and Q. Gu, *J. Nat. Prod.*, 2008, **71**, 1837–1842.
- 48 L. Du, T. Zhu, Y. Fang, H. Liu, Q. Gu and W. Zhu, *Tetrahedron*, 2007, **63**, 1085–1088.
- 49 X. Li, X. M. Li, G. M. Xu, C. S. Li and B. G. Wang, *Phytochem. Lett.*, 2014, **7**, 120–123.
- 50 W. Wang, T. Zhu, H. Tao, Z. Lu, Y. Fang, Q. Gu and W. Zhu, *J. Antibiot.*, 2007, **60**, 603–607.
- 51 I. Wijesekara, C. Zhang, Q. Van Ta, T. S. Vo, Y. X. Li and S. K. Kim, *Microbiol. Res.*, 2014, **169**, 255–261.
- 52 S. K. Agarwal, S. S. Singh, S. Verma and S. Kumar, *J. Ethnopharmacol.*, 2000, **72**, 43–46.
- 53 N. Khamthong, V. Rukachaisirikul, S. Phongpaichit, S. Preedanon and J. Sakayaroj, *Tetrahedron*, 2012, **68**, 8245–8250.



- 54 N. Khamthong, V. Rukachaisirikul, K. Tadpetch, M. Kaewpet, S. Phongpaichit, S. Preedanon and J. Sakayaroj, *Arch. Pharm. Res.*, 2012, **35**, 461–468.
- 55 A. A. El-Beih, T. Kawabata, K. Koimaru, T. Ohta and S. Tsukamoto, *Chem. Pharm. Bull.*, 2007, **55**, 1097–1098.
- 56 H. Ren, L. Tian, Q. Gu and W. Zhu, *Arch. Pharm. Res.*, 2006, **29**, 59–63.
- 57 L. Wen, Y. C. Lin, Z. G. She, D. S. Du, W. L. Chan and Z. H. Zheng, *J. Asian Nat. Prod. Res.*, 2008, **10**, 133–137.
- 58 H. J. Yan, X. M. Li, C. S. Li and B. G. Wang, *Helv. Chim. Acta*, 2012, **95**, 163–168.
- 59 W. Wang, R. Chen, Z. Luo, W. Wang and J. Chen, *Nat. Prod. Res.*, 2018, **32**, 558–563.
- 60 J. Qi, P. Zhao, L. Zhao, A. Jia, C. Liu, L. Zhang and X. Xia, *Chem. Nat. Compd.*, 2020, **56**, 112–114.
- 61 M. Isaka, P. Chinthanom, S. Veeranondha, S. Supothina and J. Jennifer Luangsa-ard, *Tetrahedron*, 2008, **64**, 11028–11033.
- 62 D. L. Li, X. M. Li and B. G. Wang, *J. Microbiol. Biotechnol.*, 2009, **19**, 675–680.
- 63 H. Anke, I. Kolthoum and H. Laatsch, *Arch. Microbiol.*, 1980, **126**, 231–236.
- 64 J. L. Li, X. Jiang, X. Liu, C. He, Y. Di, S. Lu, H. Huang, B. Lin, D. Wang and B. Fan, *Fitoterapia*, 2019, **133**, 1–4.
- 65 C. J. Wu, C. W. Li and C. Bin Cui, *Mar. Drugs*, 2014, **12**, 1815–1838.
- 66 H. Huang, F. Wang, M. Luo, Y. Chen, Y. Song, W. Zhang, S. Zhang and J. Ju, *J. Nat. Prod.*, 2012, **75**, 1346–1352.
- 67 Z. H. WU, D. LIU, Y. XU, J. L. CHEN and W. H. LIN, *Chin. J. Nat. Med.*, 2018, **16**, 219–224.
- 68 Y. M. Lee, H. Li, J. Hong, H. Y. Cho, K. S. Bae, M. A. Kim, D. K. Kim and J. H. Jung, *Arch. Pharm. Res.*, 2010, **33**, 231–235.
- 69 Y. Zhang, X. M. Li and B. G. Wang, *Biosci. Biotechnol. Biochem.*, 2012, **76**, 1774–1776.
- 70 Z. J. Wu, M. A. Ouyang, R. K. Su and Y. H. Kuo, *Chinese J. Chem.*, 2008, **26**, 759–764.
- 71 S. Q. Yang, X. M. Li, G. M. Xu, X. Li, C. Y. An and B. G. Wang, *J. Antibiot.*, 2018, **71**, 778–784.
- 72 K. W. Kim, H. J. Kim, J. H. Sohn, J. H. Yim, Y. C. Kim and H. Oh, *Neurochem. Int.*, 2018, **113**, 8–22.
- 73 X. W. Luo, H. M. Lu, X. Q. Chen, X. F. Zhou, C. H. Gao and Y. H. Liu, *Chem. Nat. Compd.*, 2020, **56**, 716–719.
- 74 A. Asai, Y. Yamashita, K. Ando, S. Kakita, K. Kita, Y. Suzuki, A. Mihara, T. Ashizawa, T. Mizukami and H. Nakano, *J. Antibiot.*, 1999, **52**, 1046–1049.
- 75 K. Sakai, S. Ohte, T. Ohshiro, D. Matsuda, R. Masuma, L. L. Rudel and H. Tomoda, *J. Antibiot.*, 2008, **61**, 568–572.
- 76 U. W. Hawas, A. A. El-Beih and A. M. El-Halawany, *Arch. Pharm. Res.*, 2012, **35**, 1749–1756.
- 77 G. C. L. Ee, Y. P. Wen, M. A. Sukari, R. Go and H. L. Lee, *Nat. Prod. Res.*, 2009, **23**, 1322–1329.
- 78 M.-I. Chung, S.-J. Jou, T.-H. Cheng, C.-N. Lin, F.-N. Ko and C.-M. Teng, *J. Nat. Prod.*, 1994, **57**, 313–316.
- 79 N. H. Yoo, D. S. Jang, Y. M. Lee, I. H. Jeong, J.-H. Cho, J.-H. Kim and J. S. Kim, *Arch. Pharm. Res.*, 2010, **33**, 209–214.
- 80 M. K. Moon, Y.-M. Han, Y.-J. Lee, L. H. Lee, J. H. Yang, B.-M. Kwon and D. K. Kim, *Arch. Pharm. Res.*, 2010, **33**, 1747–1751.
- 81 R. R. Sun, F. P. Miao, J. Zhang, G. Wang, X. L. Yin and N. Y. Ji, *Magn. Reson. Chem.*, 2013, **51**, 65–68.
- 82 J. Noinart, S. Buttachon, T. Dethoup, L. Gales, J. A. Pereira, R. Urbatzka, S. Freitas, M. Lee, A. M. S. Silva, M. M. M. Pinto, V. Vasconcelos and A. Kijjoa, *Mar. Drugs*, 2017, **15**(5), 139.
- 83 X. Yang, M. C. Kang, Y. Li, E. A. Kim, S. M. Kang and Y. J. Jeon, *J. Microbiol. Biotechnol.*, 2014, **24**, 1346–1353.
- 84 K. Y. He, C. Zhang, Y. R. Duan, G. L. Huang, C. Y. Yang, X. R. Lu, C. J. Zheng and G. Y. Chen, *J. Antibiot.*, 2017, **70**, 823–827.
- 85 P. Le Wang, D. Y. Li, L. R. Xie, X. Wu, H. M. Hua and Z. L. Li, *Nat. Prod. Res.*, 2014, **28**, 290–293.
- 86 S. Kumar, M. Yadav, A. Yadav, P. Rohilla and J. P. Yadav, *BMC Complement. Altern. Med.*, 2017, 1–10.
- 87 R. M. Cooposamy and M. L. Magwa, *Afr. J. Biotechnol.*, 2006, **5**, 1092–1094.
- 88 M. Luo, Z. Cui, H. Huang, X. Song, A. Sun, Y. Dang, L. Lu and J. Ju, *J. Nat. Prod.*, 2017, **80**, 1668–1673.
- 89 K. A. Alvi, B. Nair, C. Gallo and D. Baker, *J. Antibiot.*, 1997, **50**, 264–266.
- 90 X. M. Zhou, C. J. Zheng, G. Y. Chen, X. P. Song, C. R. Han, G. N. Li, Y. H. Fu, W. H. Chen and Z. G. Niu, *J. Nat. Prod.*, 2014, **77**, 2021–2028.
- 91 S. Huang, J. Xu, F. Li, D. Zhou, L. Xu and C. Li, *Chem. Nat. Compd.*, 2017, **53**, 237–240.
- 92 J. Li, Y. B. Zheng, T. Kurtán, M. X. Liu, H. Tang, C. L. Zhuang and W. Zhang, *Nat. Prod. Res.*, 2020, **34**, 2116–2123.
- 93 C. J. Zheng, C. L. Shao, Z. Y. Guo, J. F. Chen, D. S. Deng, K. L. Yang, Y. Y. Chen, X. M. Fu, Z. G. She, Y. C. Lin and C. Y. Wang, *J. Nat. Prod.*, 2012, **75**, 189–197.
- 94 A. H. Aly, R. A. Edrada-Ebel, V. Wray, W. E. G. Müller, S. Kozyska, U. Hentschel, P. Proksch and R. Ebel, *Phytochemistry*, 2008, **69**, 1716–1725.
- 95 J.-Y. Hwang, S. C. Park, W. S. Byun, D.-C. Oh, S. K. Lee, K.-B. Oh and J. Shin, *Mar. Drugs*, 2020, **18**, 436.
- 96 P. Phuwapraisirisan, J. Rangsang, P. Siripong and S. Tip-Pyang, *Nat. Prod. Res.*, 2009, **23**, 1063–1071.
- 97 A. Debbab, A. H. Aly, R. Edrada-Ebel, V. Wray, A. Pretsch, G. Pescitelli, T. Kurtan and P. Proksch, *European J. Org. Chem.*, 2012, 1351–1359.
- 98 C. H. Huang, J. H. Pan, B. Chen, M. Yu, H. B. Huang, X. Zhu, Y. J. Lu, Z. G. She and Y. C. Lin, *Mar. Drugs*, 2011, **9**, 832–843.
- 99 D. Pan, X. Zhang, H. Zheng, Z. Zheng, X. Nong, X. Liang, X. Ma and S. Qi, *Org. Chem. Front.*, 2019, **6**, 3252–3258.
- 100 T. Shi, X. M. Hou, Z. Y. Li, F. Cao, Y. H. Zhang, J. Y. Yu, D. L. Zhao, C. L. Shao and C. Y. Wang, *RSC Adv.*, 2018, **8**, 27596–27601.
- 101 F. Y. Du, X. M. Li, J. Y. Song, C. S. Li and B. G. Wang, *Helv. Chim. Acta*, 2014, **97**, 973–978.
- 102 Y. Li, X. Li, U. Lee, S. K. Jung, D. C. Hong and W. S. Byeng, *Chem. Pharm. Bull.*, 2006, **54**, 882–883.



Review

- 103 Y. Zhang, A. Jia, H. Chen, M. Wang, G. Ding, L. Sun, L. Li and M. Dai, *J. Antibiot.*, 2017, **70**, 1138–1141.
- 104 Y. Chen, X. Cai, J. Pan, J. Gao, J. Li, J. Yuan, L. Fu, Z. She and Y. Lin, *Magn. Reson. Chem.*, 2009, **47**, 362–365.
- 105 J. Kornsakulkarn, W. Choowong, P. Rachtawee, N. Boonyuen, S. Kongthong, M. Isaka and C. Thongpanchang, *Phytochem. Lett.*, 2018, **24**, 46–50.
- 106 H. Zhong-Jinga, Y. Run-Yunb, G. U. O. Zhi-Yongb, S. H. E. Zhi-Gangb and L. I. N. Yong-Chengb, *Chinese J. Appl. Chem.*, 2010, **5**.
- 107 X. Ge, C. Sun, Y. Feng, L. Wang, J. Peng, Q. Che, Q. Gu, T. Zhu, D. Li and G. Zhang, *Mar. Drugs*, 2019, **17**, 1–11.
- 108 X. Wang, T. Tan, Z. G. Mao, N. Lei, Z. M. Wang, B. Hu, Z. Y. Chen, Z. G. She, Y. H. Zhu and H. J. Wang, *Mar. Drugs*, 2015, **13**, 1569–1580.
- 109 X. Zhu, Z. He, J. Wu, J. Yuan, W. Wen, Y. Hu, Y. Jiang, C. Lin, Q. Zhang, M. Lin, H. Zhang, W. Yang, H. Chen, L. Zhong, Z. She, S. Chen, Y. Lin and M. Li, *Mar. Drugs*, 2012, **10**, 694–711.
- 110 C. Chen, W. Xiao, X. Jiang, J. Wang, Z. Mao, N. Lei, X. Fan, B. Song, C. Liao and H. Wang, *Curr. Med. Chem.*, 2013, **20**, 2145–2154.
- 111 S. Klaiklay, V. Rukachaisirikul, S. Phongpaichit, C. Pakawatchai, S. Saithong, J. Buatong, S. Preedanon and J. Sakayaroj, *Phytochem. Lett.*, 2012, **5**, 738–742.
- 112 G. Brauers, R. A. Edrada, R. Ebel, P. Proksch, V. Wray, A. Berg, U. Gräfe, C. Schächtele, F. Totzke, G. Finkenzeller, D. Marme, J. Kraus, M. Münchbach, M. Michel, G. Bringmann and K. Schaumann, *J. Nat. Prod.*, 2000, **63**, 739–745.
- 113 R. Jadulco, G. Brauers, R. A. Edrada, R. Ebel, V. Wray, Sudarsono and P. Proksch, *J. Nat. Prod.*, 2002, **65**, 730–733.
- 114 P. Wang, Y. Cui, C. Cai, H. Chen, Y. Dai, P. Chen, F. Kong, J. Yuan, X. Song, W. Mei and H. Dai, *Mar. Drugs*, 2019, **17**, 1–9.
- 115 Z. Niu, Y. Chen, H. Guo, S. N. Li, H. H. Li, H. X. Liu, Z. Liu and W. Zhang, *Molecules*, 2019, **24**, 1–9.
- 116 C. Shao, C. Wang, M. Wei, S. Li, Z. She, Y. Gu and Y. Lin, *Magn. Reson. Chem.*, 2008, **46**, 886–889.
- 117 H. Li, J. Wei, S. Y. Pan, J. M. Gao and J. M. Tian, *Nat. Prod. Res.*, 2014, **28**, 2358–2361.
- 118 R. P. Maskey, I. Grün-Wollny and H. Laatsch, *J. Antibiot.*, 2003, **56**, 459–463.
- 119 F. Zhu, G. Chen, X. Chen, Y. Yuan, M. Huang, W. Xiang and H. Sun, *Biomed. Eng. Informatics New Dev. Futur. - Proc. 1st Int. Conf. Biomed. Eng. Informatics, BMEI 2008*, 2008, **1**, pp. 664–667.
- 120 C. Shao, Z. She, Z. Guo, H. Peng, X. Cai, S. Zhou, Y. Gu and Y. Lin, *Magn. Reson. Chem.*, 2007, **45**, 434–438.
- 121 J. Tao, T. Morikawa, S. Ando, H. Matsuda and M. Yoshikawa, *Chem. Pharm. Bull.*, 2003, **51**, 654–662.
- 122 C. Eder, H. Kogler and L. Toti, WO 2003002549, 2003.
- 123 A. Debbab, A. H. Aly, R. A. Edrada-Ebel, V. Wray, W. E. G. Müller, F. Totzke, U. Zirrgiebel, C. Schächtele, M. H. G. Kubbutat, H. L. Wen, M. Mosaddak, A. Hakiki, P. Proksch and R. Ebel, *J. Nat. Prod.*, 2009, **72**, 626–631.
- 124 C. Shao, C. Wang, C. Zheng, Z. She, Y. Gu and Y. Lin, *Nat. Prod. Res.*, 2010, **24**, 81–85.

